UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Form 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE |
||
SECURITIES EXCHANGE ACT OF 1934 |
||
For the quarterly period ended September 30, 2003 |
||
Commission file number 001-09913
KINETIC CONCEPTS, INC.
(Exact name of registrant as specified in its charter)
Texas |
74-1891727 |
(State of Incorporation) |
(I.R.S. Employer Identification No.) |
8023 Vantage Drive
San Antonio, Texas 78230
Telephone Number: (210) 524-9000
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ___ No X
Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).
Yes ___ No X
Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.
Common Stock: 41,263,018 shares as of November 10, 2003
Condensed Consolidated Balance Sheets
Condensed Consolidated Statements of Operations
Condensed Consolidated Statements of Cash Flows
Notes to Condensed Consolidated Financial Statements ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
KINETIC CONCEPTS, INC.
INDEX
Page No. |
|||
PART I. |
FINANCIAL INFORMATION |
4 |
|
Item 1. |
Financial Statements |
4 |
|
Condensed Consolidated Balance Sheets |
4 |
||
Condensed Consolidated Statements of Operations |
5 |
||
Condensed Consolidated Statements of Cash Flows |
6 |
||
Notes to Condensed Consolidated Financial Statements |
7 |
||
Parent Company Balance Sheet, September 30, 2003 |
21 |
||
Parent Company Balance Sheet, December 31, 2002 |
22 |
||
Parent Company Statement of Operations, three months ended September 30, 2003 |
23 |
||
Parent Company Statement of Operations, three months ended September 30, 2002 |
24 |
||
Parent Company Statement of Operations, nine months ended September 30, 2003 |
25 |
||
Parent Company Statement of Operations, nine months ended September 30, 2002 |
26 |
||
Parent Company Statement of Cash Flows, nine months ended September 30, 2003 |
27 |
||
Parent Company Statement of Cash Flows, nine months ended September 30, 2002 |
28 |
||
Item 2. |
Management's Discussion and Analysis of Financial Condition and Results of Operations |
30 |
|
Item 3. |
Quantitative and Qualitative Disclosures About Market Risk |
58 |
|
Item 4. |
Controls and Procedures |
60 |
|
PART II. |
OTHER INFORMATION |
60 |
|
Item 1. |
Legal Proceedings |
60 |
|
Item 2. |
Changes in Securities and Use of Proceeds |
60 |
|
Item 4. |
Submission of Matters to a Vote of Security Holders |
61 |
|
Item 6. |
Exhibits and Reports on Form 8-K |
62 |
|
SIGNATURES |
64 |
||
CERTIFICATIONS |
65 |
PART I - FINANCIAL INFORMATION
KINETIC CONCEPTS, INC. AND SUBSIDIARIES |
||||
(in thousands) |
||||
September 30, |
December 31, |
|||
2003 |
2002 |
|||
(unaudited) |
||||
Assets: |
||||
Current assets: |
||||
Cash and cash equivalents |
$ 41,128 |
$ 54,485 |
||
Accounts receivable, net |
170,639 |
152,896 |
||
Accounts receivable - other |
- |
175,000 |
||
Inventories, net |
31,026 |
37,934 |
||
Prepaid expenses and other current assets |
16,428 |
9,760 |
||
_______ |
_______ |
|||
Total current assets |
259,221 |
430,075 |
||
_______ |
_______ |
|||
Net property, plant and equipment |
131,172 |
105,549 |
||
Loan issuance costs, less accumulated amortization |
||||
of $525 in 2003 and $11,949 in 2002 |
19,385 |
5,911 |
||
Goodwill |
48,796 |
46,357 |
||
Other assets, less accumulated amortization of |
||||
$7,332 in 2003 and $6,840 in 2002 |
30,263 |
30,167 |
||
_______ |
_______ |
|||
$ 488,837 |
$ 618,059 |
|||
_______ |
_______ |
|||
Liabilities and Shareholders' Deficit: |
||||
Current liabilities: |
||||
Accounts payable |
$ 13,843 |
$ 11,156 |
||
Accrued expenses |
92,789 |
61,556 |
||
Current installments of long-term debt |
4,950 |
30,550 |
||
Current installments of capital lease obligations |
115 |
157 |
||
Derivative financial instruments |
- |
1,341 |
||
Income taxes payable |
- |
14,615 |
||
Current deferred income taxes |
- |
66,838 |
||
_______ |
_______ |
|||
Total current liabilities |
111,697 |
186,213 |
||
_______ |
_______ |
|||
Long-term debt, net of current installments |
679,300 |
491,300 |
||
Capital lease obligations, net of current installments |
12 |
95 |
||
Derivative financial instruments |
4,601 |
- |
||
Deferred income taxes, net |
8,234 |
9,501 |
||
Deferred gain, sale of headquarters facility |
9,241 |
10,023 |
||
Other noncurrent liabilities |
213 |
1,363 |
||
_______ |
_______ |
|||
813,298 |
698,495 |
|||
Preferred stock, issued and outstanding 264 in 2003 |
255,655 |
- |
||
Shareholders' equity (deficit): |
||||
Common stock; issued and outstanding 41,166 in 2003 and 70,928 in 2002 |
41 |
71 |
||
Deferred compensation |
(451) |
- |
||
Retained deficit |
(580,240) |
(76,216) |
||
Accumulated other comprehensive income (loss) |
534 |
(4,291) |
||
_______ |
_______ |
|||
Shareholders' deficit |
(580,116) |
(80,436) |
||
_______ |
_______ |
|||
$ 488,837 |
$ 618,059 |
|||
_______ |
_______ |
|||
See accompanying notes to condensed consolidated financial statements. |
Table of Contents
KINETIC CONCEPTS, INC. AND SUBSIDIARIES |
||||||||
Three months ended |
Nine months ended |
|||||||
September 30, |
September 30, |
|||||||
2003 |
2002 |
2003 |
2002 |
|||||
Revenue: |
||||||||
Rental and service |
$ 151,159 |
$ 116,051 |
$ 421,455 |
$ 325,061 |
||||
Sales and other |
46,883 |
34,836 |
126,467 |
90,714 |
||||
_______ |
_______ |
_______ |
_______ |
|||||
Total revenue |
198,042 |
150,887 |
547,922 |
415,775 |
||||
_______ |
_______ |
_______ |
_______ |
|||||
Rental expenses |
92,518 |
70,272 |
259,808 |
199,326 |
||||
Cost of goods sold |
18,052 |
15,263 |
46,410 |
36,632 |
||||
_______ |
_______ |
_______ |
_______ |
|||||
Gross profit |
87,472 |
65,352 |
241,704 |
179,817 |
||||
Selling, general and administrative expenses |
48,701 |
38,954 |
134,096 |
102,717 |
||||
Recapitalization expenses |
69,955 |
- |
69,955 |
- |
||||
_______ |
_______ |
_______ |
_______ |
|||||
Operating earnings (loss) |
(31,184) |
26,398 |
37,653 |
77,100 |
||||
Interest income |
186 |
169 |
933 |
278 |
||||
Interest expense |
(25,334) |
(10,185) |
(41,562) |
(30,877) |
||||
Foreign currency gain (loss) |
1,527 |
(395) |
5,683 |
2,053 |
||||
_______ |
_______ |
_______ |
_______ |
|||||
Earnings (loss) before income taxes (benefit) |
(54,805) |
15,987 |
2,707 |
48,554 |
||||
Income taxes (benefit) |
(20,552) |
6,884 |
1,015 |
19,422 |
||||
_______ |
_______ |
_______ |
_______ |
|||||
Net earnings (loss) |
$ (34,253) |
$ 9,103 |
$ 1,692 |
$ 29,132 |
||||
_______ |
_______ |
_______ |
_______ |
|||||
Less: Preferred stock dividends |
(3,427) |
- |
(3,427) |
- |
||||
_______ |
_______ |
_______ |
_______ |
|||||
Net earnings (loss) to common shareholders |
$ (37,680) |
$ 9,103 |
$ (1,735) |
$ 29,132 |
||||
_______ |
_______ |
_______ |
_______ |
|||||
Basic earnings (loss) per common share |
$ (0.74) |
$ 0.13 |
$ (0.03) |
$ 0.41 |
||||
_______ |
_______ |
_______ |
_______ |
|||||
Diluted earnings (loss) per common share |
$ (0.74) |
$ 0.12 |
$ (0.03) |
$ 0.38 |
||||
_______ |
_______ |
_______ |
_______ |
|||||
Average common shares: |
||||||||
Basic (weighted average |
||||||||
outstanding shares) |
51,139 |
70,928 |
64,398 |
70,927 |
||||
|
_______ |
_______ |
_______ |
_______ |
||||
Diluted (weighted average |
||||||||
outstanding shares) |
51,139 |
77,664 |
64,398 |
77,674 |
||||
_______ |
_______ |
_______ |
_______ |
|||||
See accompanying notes to condensed consolidated financial statements. |
Table of Contents
KINETIC CONCEPTS, INC. AND SUBSIDIARIES |
|||
(in thousands) |
|||
(unaudited) |
|||
Nine months ended September 30, |
|||
2003 |
2002 |
||
Cash flows from operating activities: |
|||
Net earnings |
$ 1,692 |
$ 29,132 |
|
Adjustments to reconcile net earnings to net cash provided by operating activities: |
|||
Depreciation |
32,228 |
24,176 |
|
Amortization |
2,263 |
2,883 |
|
Provision for uncollectible accounts receivable |
5,132 |
6,946 |
|
Amortization of deferred gain on sale of headquarters facility |
(782) |
(171) |
|
Write-off of deferred loan issuance costs |
5,233 |
- |
|
Non-cash accrual of recapitalization expenses |
8,907 |
- |
|
Non-cash amortization of stock award to directors |
92 |
- |
|
Change in assets and liabilities net of effects from purchase of subsidiaries and recapitalization expenses |
|||
Increase in accounts receivable, net |
(21,638) |
(22,973) |
|
Decrease in other accounts receivable |
175,000 |
- |
|
Decrease in inventories |
7,397 |
1,351 |
|
Increase in prepaid expenses and other current assets |
(6,662) |
(7,972) |
|
Increase in accounts payable |
2,824 |
884 |
|
Increase in accrued expenses |
22,910 |
8,475 |
|
Increase (decrease) in income taxes payable |
(14,615) |
3,510 |
|
Decrease in current deferred income taxes |
(66,838) |
- |
|
Decrease (increase) in deferred income taxes, net |
(126 ) |
6,604 |
|
Net cash provided by operating activities |
153,017 |
52,845 |
|
_______ |
_______ |
||
Cash flows from investing activities: |
|||
Additions to property, plant and equipment |
(56,649) |
(43,842) |
|
Decrease in inventory to be converted into equipment for short-term rental |
800 |
2,400 |
|
Dispositions of property, plant and equipment |
1,590 |
2,598 |
|
Proceeds from sale of headquarters facility |
- |
17,924 |
|
Business acquisitions, net of cash acquired |
(2,224) |
(3,596) |
|
Increase in other assets |
(351 ) |
(842) |
|
Net cash used by investing activities |
(56,834) |
(25,358) |
|
_______ |
_______ |
||
Cash flows from financing activities: |
|||
Proceeds from (repayment of) notes payable, long term, capital lease and other obligations |
(116,100) |
16,700 |
|
Proceeds from exercise of stock options |
903 |
8 |
|
Recapitalization: |
|||
Payoff of long term debt and bonds |
(408,226) |
- |
|
Proceeds from issuance of new debt and bonds |
685,000 |
- |
|
Proceeds from issuance of preferred stock, net |
258,017 |
- |
|
Purchase of common stock |
(509,597) |
- |
|
Debt and preferred stock issuance costs |
(20,729 ) |
- |
|
Net cash provided (used) by financing activities |
(110,732) |
16,708 |
|
_______ |
_______ |
||
Effect of exchange rate changes on cash and cash equivalents |
1,192 |
513 |
|
Net increase (decrease) in cash and cash equivalents |
(13,357) |
44,708 |
|
Cash and cash equivalents, beginning of period |
54,485 |
199 |
|
Cash and cash equivalents, end of period |
$ 41,128 |
$ 44,907 |
|
Cash paid during the nine months for: |
|||
Interest |
$ 34,657 |
(1) |
$ 24,508 |
Income taxes |
$ 83,812 |
(2) |
$ 12,603 |
(1) Includes $11.1 million of expenses related to the recapitalization, including $9.6 million related to redemption premium |
|||
and approximately $1.5 million related to early redemption consent fees on our 9 5/8% Senior Subordinated Notes |
|||
(2) Includes $66.8 million of income taxes paid related to the Hillenbrand antitrust settlement. |
|||
See accompanying notes to condensed consolidated financial statements. |
KINETIC CONCEPTS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
(1) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
(a) Basis of Presentation
The unaudited condensed consolidated financial statements presented herein include the accounts of Kinetic Concepts, Inc., together with our consolidated subsidiaries ("KCI"). The unaudited condensed consolidated financial statements appearing in this quarterly report on Form 10-Q should be read in conjunction with the financial statements and notes thereto included in KCI's latest annual report on Form 10-K. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a fair presentation of results of operations, financial position and cash flows in conformity with accounting principles generally accepted in the United States. Operating results from interim pe riods are not necessarily indicative of results that may be expected for the fiscal year as a whole. In our opinion, the consolidated financial statements reflect all adjustments considered necessary for a fair presentation of our results for the periods presented. Certain reclassifications of amounts related to the prior year have been made to conform with the 2003 presentation, including, but not limited to, the reclassification of shipping and handling costs billed to customers from rental expense to other revenue.
(b) Stock Options
We use the intrinsic value method to account for our stock option plans. In the first nine months of 2003 and 2002, compensation costs of approximately $43.9 million and $567,000 respectively, net of estimated taxes, have been recognized in the financial statements related to our plans. Compensation costs for 2003 include $42.2 million of expenses, net of taxes, related to the recapitalization. If the compensation cost for our stock-based employee compensation plan had been determined based upon a fair value method consistent with Statement of Financial Accounting Standards No. 123 ("SFAS 123"), "Accounting for Stock-Based Compensation," our net earnings to common shareholders and earnings per share would have been adjusted to the pro forma amounts indicated below. For purposes of pro forma disclosures, the estimated fair value of the options is recognized as an expense over the options' respective vesting periods. Our pro forma calculations are as follows (dollars in thousands, except for earnings per share information):
Three months ended |
Nine months ended |
|||||||||
2003 |
2002 |
2003 |
2002 |
|||||||
Net earnings (loss) to common shareholders |
||||||||||
as reported |
$ (37,680) |
$ 9,103 |
$ (1,735) |
$ 29,132 |
||||||
Pro forma net earnings: |
||||||||||
Net earnings (loss) to common |
||||||||||
shareholders as reported |
$ (37,680) |
$ 9,103 |
$ (1,735) |
$ 29,132 |
||||||
Compensation charge under intrinsic method |
42,209 |
243 |
43,855 |
567 |
||||||
Compensation expense under fair value method |
(3,957) |
(359) |
(4,732) |
(1,093) |
||||||
______ |
______ |
______ |
______ |
|||||||
Pro forma net earnings |
$ 572 |
$ 8,987 |
$ 37,388 |
$ 28,606 |
||||||
______ |
______ |
______ |
______ |
|||||||
Earnings (loss) per share as reported |
||||||||||
Basic earnings (loss) per common share |
$ (0.74) |
$ 0.13 |
$ (0.03) |
$ 0.41 |
||||||
Diluted earnings (loss) per common share |
$ (0.74) |
$ 0.12 |
$ (0.03) |
$ 0.38 |
||||||
Pro forma earnings per share |
||||||||||
Basic earnings per common share |
$ 0.01 |
$ 0.13 |
$ 0.58 |
$ 0.40 |
||||||
Diluted earnings per common share |
$ 0.01 |
$ 0.12 |
$ 0.51 |
$ 0.37 |
Table of Contents
We are not required to apply, and have not applied, the method of accounting prescribed by SFAS 123 to stock options granted prior to January 1, 1995. Moreover, the pro forma compensation cost reflected above may not be representative of future expense.
(c) Self-Insurance
We established the KCI employee benefit trust as a self-insurer for certain risks related to our U.S. employee health plan and certain other benefits. We retain various levels of loss related to certain of our benefits including all short-term disability claims and losses under our Texas Employee Injury Plan up to $500,000 per occurrence. Our health, group life and accidental death and dismemberment plan along with our long-term disability plan are all fully insured. We fund the benefit trust based on the value of expected future payments, including claims incurred but not reported. The liability for retained losses is determined actuarially. These liabilities are not discounted.
(d) Other New Accounting Pronouncements
In January 2003, the Financial Accounting Standards Board ("FASB") issued Interpretation No. 46, or ("FIN 46"), "Consolidation of Variable Interest Entities." This interpretation is now effective for fiscal years or interim periods ending after December 15, 2003. FIN 46 addresses accounting for, and disclosure of, variable interest entities. FIN 46 requires the disclosure of the nature, purpose and exposure of any loss related to our involvement with variable interest entities. We adopted the provisions of FIN 46 for post-January 31, 2003 variable interest entities during the first quarter of 2003 and it did not have a significant effect on our financial position or results of operations. We continue to evaluate the potential effects of the consolidation provisions of FIN 46 that will be adopted during the fourth quarter of 2003.
Specifically, we are evaluating the consolidation provisions of FIN 46 on our beneficial ownership of two Grantor Trusts, which we acquired in December 1996 and December 1994. The assets held by each Trust consist of a McDonnell Douglas DC-10 aircraft and three engines. In connection with the acquisitions, KCI paid cash of $7.2 million and $7.6 million, respectively. At the date of acquisition, the Trusts held debt of $48.4 million and $51.8 million, respectively, which is non-recourse to KCI. The aircraft are leased to the Federal Express Corporation through June 2012 and January 2012, respectively. Federal Express pays monthly rent to a third party who, in turn, pays the entire amount to the holders of the non-recourse indebtedness, which is secured by the aircraft. The holder's recourse in event of a default is limited to the Trusts assets.
In April 2003, the FASB issued Statement of Financial Accounting Standards No. 149, or ("SFAS 149"), "Amendment of Statement 133 on Derivative Instruments and Hedging Activities." This statement amends SFAS 133 to provide clarification on the financial accounting and reporting of derivative instruments and hedging activities and requires contracts with similar characteristics to be accounted for on a comparable basis. We do not expect the adoption of SFAS 149, which will be effective for contracts entered into or modified after September 30, 2003, to have a material effect on our financial condition or results of operations.
On May 15, 2003, the FASB issued SFAS 150, "Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity." The statement established standards for classifying and measuring as liabilities certain financial instruments that embody obligations of the issuer and have characteristics of both liabilities and equity. SFAS 150 must be applied immediately to instruments entered into or modified after May 31, 2003. We have applied the terms of SFAS 150 to the convertible preferred stock issued as a part of the recapitalization and determined that it should be classified as equity and will be reported in the mezzanine section of our balance sheet. All dividends paid or accrued on the preferred stock will be reported as dividends in the Condensed Consolidated Statements of Operations.
Table of Contents(e) Other Significant Accounting Policies
For further information, see Note 1 to the consolidated financial statements included in KCI's Annual Report on Form 10-K for the year ended December 31, 2002.
(2) RECAPITALIZATION
Issuance of 7 3/8% Senior Subordinated Notes. On August 11, 2003, we issued and sold an aggregate of $205.0 million principal amount of our 7 3/8% Senior Subordinated Notes due 2013. Our obligations under the notes are fully and unconditionally guaranteed, jointly and severally, on a senior subordinated basis, by most of our direct and indirect domestic subsidiaries. (See Note 5.)
New Senior Credit Facility. Concurrently with the issuance and sale of the notes, we entered into a new senior credit facility. The senior credit facility consists of a $480.0 million seven-year term loan facility and an undrawn $100.0 million six-year revolving credit facility. Initially, we borrowed $480.0 million under the new term loan facility. We used $208.2 million of the proceeds from borrowings under the new credit facility to repay all amounts then outstanding under our previously existing senior credit facility. Borrowings under the new senior credit facility are secured by a first priority security interest in substantially all of our existing and hereafter acquired assets, including substantially all of the capital stock or membership interests of all of our subsidiaries that are guarantors under the new credit facility and 65% of the capital stock or membership interests of certain of our foreign subsidiaries. (See Note 5.)
Issuance of Preferred Stock. Concurrently with the issuance and sale of the notes, we also issued and sold $263.8 million of our Series A Convertible Participating Preferred Stock, par value $.001 per share. (See Note 6.)
Redemption of 9 5/8% Senior Subordinated Notes. As of August 11, 2003, we had outstanding $200.0 million in 9 5/8% Senior Subordinated Notes due 2007. On that date, we notified holders of the notes that, pursuant to their terms, we would redeem all such outstanding notes for a purchase price of 104.813% of their principal amount plus accrued but unpaid interest to the date of redemption. The redemption was completed on August 14, 2003. In addition, we paid approximately $1.5 million in early redemption consent fees related to these notes. (See Note 5.)
Share Repurchase. On August 11, 2003, we commenced a tender offer to purchase for cash up to $589.8 million of our common stock and vested stock options at a price equivalent to $17.00 per share of common stock. Upon closing, we purchased and retired 30.0 million shares of outstanding common stock for $17.00 per share. We also settled for cash 4.7 million vested stock options at a price equivalent to $17.00 per share of common stock. In the first quarter of 2004, we may offer to repurchase additional shares and vested stock options in an amount equal to the sum of the following:
- the net after-tax proceeds of the $75.0 million Hillenbrand antitrust settlement that we expect to receive in
January 2004;
- the remaining tax benefits to KCI, not previously paid out, related to the recapitalization in an amount not to
exceed $40.0 million; and
- the cash received from the exercise of employee stock options as part of the share repurchase.
The issuance and sale of the 7 3/8% Senior Subordinated Notes due 2013 and the preferred stock, the repayment of our old senior credit facility with proceeds from the new senior credit facility, the redemption of our 9 5/8% senior subordinated notes due 2007 and the share repurchase are referred to herein collectively as the "recapitalization."
Table of ContentsThe following sets forth the sources and uses of funds in connection with the recapitalization (dollars in millions)
:
Amount |
|
Source of Funds: |
|
Gross proceeds from the sale of the 7 3/8% Senior Subordinated Notes Due 2013 |
$ 205.0 |
Borrowings under the new senior credit facility |
480.0 |
Gross proceeds from the sale of convertible preferred stock |
263.8 |
Proceeds from Hillenbrand antitrust settlement (net of taxes) |
46.9 |
Tax benefits realized from transaction fees and expenses |
32.3 |
Cash on hand |
53.4 |
______ |
|
Total |
$ 1,081.4 |
______ |
|
Use of Funds: |
|
Redemption of 9 5/8% Senior Subordinated Notes Due 2007(1) |
$ 211.1 |
Repayment of debt under the old senior credit facility |
208.2 |
Share repurchase (2) |
634.0 |
Transaction fees and expenses for the recapitalization |
28.1 |
______ |
|
Total |
$ 1,081.4 |
______ |
(1) Includes early redemption premium of 4.813% of the aggregate principal amount pursuant to the terms of the 9 5/8%
Senior Subordinated Notes due 2007, in addition to the payment of approximately $1.5 million in early redemption
consent fees related to amending these notes.
(2) Includes anticipated share repurchase discussed above
Our September 30, 2003 three-month and nine-month results reflect the impact of the recapitalization including a charge to earnings of $86.3 million, before tax benefits related to the recapitalization of $32.3 million. The charge to earnings, pretax, included a $67.5 million charge to compensation expense for the repurchase, or cash settlement, of vested options, together with $11.1 million in expenses for the payment of a consent fee and an early redemption premium related to the redemption of the 9 5/8% Senior Subordinated Notes due 2007. Additionally, we wrote off debt issuance costs related to our old senior credit facility and the 9 5/8% Senior Subordinated Notes due 2007 totaling approximately $5.2 million, pretax. The remaining expenses of approximately $2.5 million, pretax, were related to miscellaneous fees and expenses associated with the share repurchase. Both the premium paid on the redemption of our 9 5/8% Senior Subordinated Notes and the write-off of commitment fees on unused credit facilities were charged to interest expense. Financing costs of approximately $19.8 million have been deferred and will be amortized over the lives of the debt facilities. Direct and incremental costs related to the issuance of the preferred stock of approximately $950,000 have been deferred and will be amortized over 12 years unless the preferred stock is previously converted or redeemed. (See Note 6.)
Table of Contents(3) ACCOUNTS RECEIVABLE COMPONENTS
Accounts receivable consist of the following (dollars in thousands):
September 30, |
December 31, |
||
2003 |
2002 |
||
Trade accounts receivable: |
|||
Facilities / dealers |
$ 108,790 |
$ 91,756 |
|
Third party payers: |
|||
Medicare / Medicaid |
33,308 |
31,721 |
|
Managed care, insurance and other |
60,648 |
53,229 |
|
_______ |
_______ |
||
202,746 |
176,706 |
||
Medicare V.A.C. receivables prior to |
|||
October 1, 2000 |
13,682 |
14,351 |
|
Employee and other receivables |
1,993 |
2,410 |
|
_______ |
_______ |
||
218,421 |
193,467 |
||
Less: Allowance for doubtful accounts |
(34,100) |
(26,220) |
|
Allowance for Medicare V.A.C. receivables |
|||
prior to October 1, 2000 |
(13,682) |
(14,351) |
|
_______ |
_______ |
||
$ 170,639 |
$ 152,896 |
||
_______ |
_______ |
(4) INVENTORY COMPONENTS
Inventories are stated at the lower of cost (first-in, first-out) or market (net realizable value). Inventories are comprised of the following (dollars in thousands):
September 30, |
December 31, |
||
2003 |
2002 |
||
Finished goods |
$ 12,257 |
$ 16,411 |
|
Work in process |
2,579 |
2,411 |
|
Raw materials, supplies and parts |
29,314 |
31,825 |
|
______ |
______ |
||
44,150 |
50,647 |
||
Less: Amounts expected to be converted |
|||
into equipment for short-term rental |
(10,300) |
(11,100) |
|
Reserve for excess and obsolete |
|||
inventory |
(2,824) |
(1,613) |
|
______ |
______ |
||
$ 31,026 |
$ 37,934 |
||
______ |
______ |
Table of Contents
(5) LONG-TERM OBLIGATIONS AND DERIVATIVE FINANCIAL INSTRUMENTS
Long-term obligations consist of the following (dollars in thousands):
September 30, |
December 31, |
||
|
2003 |
2002 |
|
2003 Senior Credit Facility: |
|||
Term loan B due 2010 |
$ 478,800 |
$ - |
|
Revolving credit facility due 2009 |
- |
- |
|
Previous Senior Credit Facility: |
|||
Term loans: |
|||
Tranche A due 2003 |
- |
27,500 |
|
Tranche B due 2004 |
- |
85,500 |
|
Tranche C due 2005 |
- |
85,500 |
|
Tranche D due 2006 |
- |
93,575 |
|
Tranche E due 2005 |
- |
29,775 |
|
Revolving credit facility |
- |
- |
|
_______ |
_______ |
||
478,800 |
321,850 |
||
7 3/8% Senior Subordinated Notes due 2013 |
205,000 |
- |
|
9 5/8% Senior Subordinated Notes due 2007 |
- |
200,000 |
|
Note Payable - MedClaims |
450 |
- |
|
_______ |
_______ |
||
684,250 |
521,850 |
||
Less current installments |
(4,950) |
(30,550) |
|
_______ |
_______ |
||
$ 679,300 |
$ 491,300 |
||
_______ |
_______ |
New Senior Credit Facility
On August 11, 2003, we entered into a new senior credit facility consisting of a $480.0 million term loan facility due 2010 and an undrawn $100.0 million revolving credit facility.
Loans. The senior credit facility consists of a $480.0 million term loan facility and an undrawn $100.0 million revolving credit facility. Up to $30.0 million of the revolving credit facility is available for letters of credit. At September 30, 2003, $478.8 million was outstanding under the term loan facility and we had no revolving loans outstanding. However, we had outstanding six letters of credit in the aggregate amount of $11.3 million. The resulting availability under the revolving credit facility was $88.7 million at September 30, 2003.
Interest. Amounts outstanding under the senior credit facility bear interest at a rate equal to the base rate (defined as the higher of Citibank, N.A.'s prime rate or 1/2 of 1% in excess of the federal funds rate) or the Eurodollar rate (the reserve-adjusted LIBOR rate), in each case plus an applicable margin. The applicable margin is equal to (a) with respect to the new revolving credit facility, 2.50% in the case of loans based on the Eurodollar rate and 1.50% in the case of loans based on the base rate and (b) with respect to the new term loan B facility, (1) at any time that the leverage ratio is greater than 3.00 to 1.00, 2.75% in the case of loans based on the Eurodollar rate and 1.75% in the case of loans based on the base rate and (2) 2.50 at any other time, in the case of loans based on the Eurodollar rate and 1.50% in the case of loans based on the base rate.
We may choose base rate or Eurodollar pricing and may elect interest periods of 1, 2, 3 or 6 months for the Eurodollar borrowings. Interest on base rate borrowings is payable quarterly in arrears. Interest on Eurodollar borrowings is payable at the end of each applicable interest period or every three months in the case of interest periods in excess of three months. Interest on all past due amounts will accrue at 2.00% over the applicable rate. The senior credit facility requires that we fix the base-borrowing rate applicable to at least 50% of the outstanding amount of the term loan under the senior credit facility. As of September 30, 2003, the current
Table of Contentsinterest rate swap agreements effectively fix the base-borrowing rate on 89.8% of our outstanding amounts under the term loan facility.
Collateral. The senior credit facility is secured by a first priority lien and security interest in (a) substantially all shares of capital stock and intercompany debt of each of our present and future subsidiaries (limited in the case of certain foreign subsidiaries to 65% of the voting stock of such entity) (b) substantially all of our present and future real property (with a value in excess of $5 million individually) and assets and the present and future personal property and assets of our subsidiaries that will be guarantors under the senior credit facility and (c) all proceeds and products of the property and assets described in (a) and (b) above. The security interest is subject to certain exceptions and permitted liens.
Guarantors. Our obligations under the senior credit facility are guaranteed by each of our direct and indirect 100% owned subsidiaries, other than a controlled foreign corporation within the definition of Section 957 of the Internal Revenue Code or a holding company whose only assets are investments in a controlled foreign corporation.
Repayments. Amounts available under the new revolving credit facility are available for borrowing and reborrowing until maturity. No amounts repaid under the term loan B facility may be reborrowed.
Maturity. The term loan facility matures on August 11, 2010. The revolving credit facility matures on August 11, 2009.
Prepayments. We may prepay, in full or in part, borrowings under the senior credit facility without premium or penalty, subject to minimum prepayment amount and increment limitations. We are required to prepay borrowings under the senior credit facility from certain asset dispositions, debt issuances and equity issuances and beginning after fiscal year 2004 a percentage of excess cash flow, subject to customary exceptions.
Covenants. The senior credit facility contains affirmative and negative convents customary for similar facilities and transactions. Set forth herein is a description of the material covenants, which include, but are not limited to, quarterly and annual financial reporting requirements and limitations on other debt, other liens or guarantees, mergers or consolidations, asset sales, certain investments, distributions to shareholders or share repurchases, early retirement of subordinated debt, capital expenditures, changes in the nature of the business, changes in organizational documents and documents evidencing or related to indebtedness that are materially adverse to the interests of the lenders under the senior credit facility and changes in accounting policies or reporting practices.
The senior credit facility contains financial covenants requiring us to meet certain leverage and interest coverage ratios and maintain minimum levels of EBITDA (as defined in the senior credit agreement). Under the senior credit agreement, EBITDA excludes charges associated with the recapitalization. It will be an event of default if we permit any of the following:
- for any period of four consecutive quarters ending at the end of any fiscal quarter beginning with the fiscal
quarter ending December 31, 2003, the ratio of EBITDA, as defined, to consolidated cash interest expense,
to be less than certain specified ratios ranging from 4.30 to 1.00 for the fiscal quarter ending December 31,
2003 to 5.50 to 1.00 for the fiscal quarter ending December 31, 2006 and each fiscal quarter following that
quarter;
- as of the last day of any fiscal quarter beginning with the fiscal quarter ending December 31, 2003, our
leverage ratio of debt to EBITDA, as defined, to be greater than certain specified leverage ratios ranging
from 4.30 to 1.00 for the fiscal quarter ending December 31, 2003 to 2.50 to 1.00 for the fiscal quarter
ending December 31, 2006 and each fiscal quarter following that quarter; or
- for any period of four consecutive fiscal quarters ending at the end of any fiscal quarter beginning
with the fiscal quarter ending December 31, 2003, EBITDA, as defined, to be less than certain amounts
ranging from $156.4 million for the fiscal quarter ending December 31, 2003 to
$240.0 million for the fiscal quarter ending December 31, 2006 and each fiscal quarter following that
quarter.
Events of Default. The 2003 senior credit facility contains events of default including, but not limited to, failure to pay principal or interest, breaches of representations and warranties, violations of affirmative or negative convenants, cross-defaults to other indebtedness, a bankruptcy or similar proceeding being instituted by or against us, rendering of certain monetary judgments against us, impairments of loan documentation or security, changes of ownership or operating control and defaults with respect to certain ERISA obligations.
7 3/8% Senior Subordinated Notes due 2013
On August 11, 2003, we issued and sold an aggregate of $205.0 million principal amount of our 7 3/8% Senior Subordinated Notes due 2013. Interest on the notes accrues at the rate of 7 3/8% per annum and is payable semi-annually in cash on each May 15 and November 15, commencing on November 15, 2003, to the persons who are registered holders at the close of business on May 1 and November 1 immediately preceding the applicable interest payment date. Interest on the notes accrues from and includes the most recent date to which interest has been paid or, if no interest has been paid, from and including the date of issuance of the notes. Interest is computed on the basis of a 360-day year consisting of twelve 30-day months and, in the case of a partial month, the actual number of days elapsed. The notes are not entitled to the benefit of any mandatory sinking fund.
The notes are unsecured obligations of KCI, ranking subordinate in right of payment to all senior debt of KCI. The notes are guaranteed by each of our direct and indirect 100% owned subsidiaries, other than any entity that is a controlled foreign corporation within the definition of Section 957 of the Internal Revenue code or a holding company whose only assets are investments in a controlled foreign corporation. Each of these subsidiaries is a restricted subsidiary, as defined in the indenture governing the notes. The new notes are guaranteed by the following subsidiaries of KCI:
1. |
KCI Holding Company, Inc |
6. |
KCI Real Properties Limited |
|
2. |
KCI Real Holdings, LLC |
7. |
KCI USA, Inc. |
|
3. |
KCI International, Inc. |
8. |
KCI USA Real Holdings, LLC |
|
4. |
KCI Licensing, Inc |
9. |
MedClaim, Inc. |
|
5. |
KCI Properties Limited |
The following entities were formerly guarantors of the recently redeemed 9 5/8% Senior Subordinated Notes due 2007, but are not guarantors of the recently issued 7 3/8% Senior Subordinated Notes due 2013.
1. |
KCI Therapeutic Services, Inc. |
|
2. |
KCI New Technologies, Inc. |
|
3. |
KCI Air, Inc. |
|
4. |
KCI-RIK Acquisition Corp. |
|
5. |
Plexus Enterprises, Inc. |
|
6. |
Medical Retro Design, Inc. |
Each of these entities no longer exists due to a corporate change such as dissolution or merger into an existing KCI subsidiary. However, the assets of each of these former guarantors remain in the consolidated group.
Each guarantor jointly and severally guarantees KCI's obligation under the notes. The guarantees are subordinated to guarantor senior debt on the same basis as the notes are subordinated to senior debt. The obligations of each guarantor under its guarantor senior debt will be limited as necessary to prevent the guarantor senior debt from constituting a fraudulent conveyance under applicable law.
The indenture governing the notes, limits our ability, among other things, to:
Table of Contents - incur additional debt;
- pay dividends, acquire shares of capital stock, make payments on subordinated debt or make investments;
- place limitations on distributions from our restricted subsidiaries;
- issue or sell capital stock of restricted subsidiaries;
- issue guarantees;
- sell or exchange assets;
- enter into transactions with affiliates;
- create liens; and
- effect mergers.
KCI may redeem some or all of the notes, on and after May 15, 2008, upon not less than 30 nor more than 60 days' notice, at the following redemption prices (expressed as percentages of the principal amount) if redeemed during the twelve-month period commencing on May 15 of the year set forth below, plus, in each case, accrued and unpaid interest thereon, if any, to the date of redemption:
If Redeemed During the 12-Month Period Commencing |
Redemption Price |
2008 |
103.688% |
2009 |
102.458% |
2010 |
101.229% |
2011 and thereafter |
100.000% |
In addition, at any time prior to May 15, 2008, we may, at our option, redeem the notes, in whole or in part, from time to time, upon not less than 30 nor more than 60 days' notice at a redemption price equal to the greater of (a) 101% of the principal amount of the notes so redeemed, plus accrued and unpaid interest, and (b) a make-whole premium (as defined in the indenture) with respect to the notes, or the portions thereof, to be redeemed, plus, to the extent not included in the make-whole premium, accrued and unpaid interest to the date of redemption.
At any time, or from time to time, on or prior to May 15, 2006, we may, on any one or more occasions use all or a portion of the net cash proceeds of one or more equity offerings to redeem the notes at a redemption price equal to 107.375% of the principal amount thereof plus accrued and unpaid interest thereon, if any, to the date of redemption; provided that at least 65% of the principal amount of notes originally issued remains outstanding immediately after any such redemption. In order to effect the foregoing redemption with the proceeds of any equity offering, we shall make such redemption not more than 90 days after the consummation of any such equity offering.
Interest Rate Protection
We follow SFAS 133, "Accounting for Derivative Instruments and Hedging Activities," and its amendments, SFAS 137 and 138, in accounting for our derivative instruments. SFAS 133 requires that all derivative instruments be recorded on the balance sheet at fair value. We have designated our interest rate swap agreements as cash flow hedge instruments. The swap agreements are used to manage exposure to interest rate movements by effectively changing the variable interest rate to a fixed rate. The critical terms of the interest rate swap agreements and the interest-bearing debt associated with the swap agreements must be the same to qualify for the shortcut method of accounting. Changes in the effective portion of the fair value of the interest rate swap agreement will be recognized in other comprehensive income, net of tax effects, until the hedged item is recognized into earnings.
Table of ContentsThe following chart summarizes interest rate hedge transactions effective during the first nine months of 2003 (dollars in thousands):
Nominal |
Fixed |
||||||
Accounting Method |
Effective Dates |
Amount |
Interest Rate |
Status |
|||
Shortcut |
12/31/02 - 12/31/03 |
$ 80,000 |
1.745% |
Outstanding |
|||
Shortcut |
12/31/02 - 12/31/04 |
$ 100,000 |
2.375% |
Outstanding |
|||
Shortcut |
08/21/03 - 08/22/05 |
$ 60,000 |
2.150% |
Outstanding |
|||
Shortcut |
08/21/03 - 08/22/05 |
$ 20,000 |
2.130% |
Outstanding |
|||
Shortcut |
08/21/03 - 08/21/05 |
$ 20,000 |
2.135% |
Outstanding |
|||
Shortcut |
08/21/03 - 08/21/06 |
$ 50,000 |
2.755% |
Outstanding |
|||
Shortcut |
08/21/03 - 08/21/06 |
$ 50,000 |
2.778% |
Outstanding |
|||
Shortcut |
08/21/03 - 08/21/06 |
$ 50,000 |
2.788% |
Outstanding |
As of December 31, 2002, two $100 million interest rate swap agreements were in effect to take advantage of low interest rates. On January 31, 2003, we sold $20 million of our $100 million, 1.7450% interest rate swap effective March 31, 2003 which resulted in an expense of approximately $74,000 which was recorded in the first quarter of 2003. Our 2003 senior credit facility requires that we fix the base-borrowing rate applicable to at least 50% of the outstanding amount of our term loan under the senior credit facility for a period of two years from the date of issuance. In August 2003, we entered into six new interest rate swap agreements pursuant to which we fixed the rates on an additional $250 million of our variable rate debt. As a result of the eight swap agreements currently in effect as of September 30, 2003, 89.8% of our variable interest rate debt outstanding is fixed.
All of the interest rate swap agreements have quarterly interest payments, based on three month LIBOR, due on the last day of each March, June, September and December, commencing on September 30, 2003. The fair value of these swaps at inception was zero. Due to subsequent movements in interest rates, as of September 30, 2003, the fair values of these swap agreements were negative and were adjusted to reflect a liability of approximately $4.6 million. During the first nine months of 2003 and 2002, we recorded interest expense of approximately $1.6 million and $2.0 million, respectively, as a result of interest rate protection agreements.
(6) PREFERRED STOCK
On August 9, 2003, in accordance with our Articles of Incorporation, the board of directors of KCI approved the creation of a class of preferred stock designated as Series A Convertible Participating Preferred Stock with a par value of $0.001 per share. On August 11, 2003, we issued a total of 263,800 shares of the preferred stock at an original issue price and stated value of $1,000 per share. The preferred stock is convertible to common stock at a ratio of $17.00 per share of common stock (the estimated fair value of the common stock at the date of issuance). The preferred stock accrues cumulative dividends
quarterly at the rate of 9% per annum (or the dividends paid on common stock, whichever is greater), and must be paid in kind for the first three years from the date of issuance, and after that point may be paid in cash or in kind, at KCI's option. We recorded dividends-in-kind of $3.3 million during t he three months ended September 30, 2003.Upon an initial public offering above $22.00 per share, or upon 20 consecutive post-initial public offering trading days for which the trading price of the common exceeds $23.50, the preferred stock is mandatorily convertible into common stock. If we have an initial public offering at less than $22.00 per share, we can force conversion if it makes the holders of the preferred whole for the shortfall between the initial public offering price and $22.00 per share. Additionally, if the conversion has not been triggered based on trading price, we can force conversion by making the preferred holders whole by issuing them additional common stock as if they had converted at a value of $23.50 per share.
Table of ContentsIf, prior to December 31, 2005, conversion of the preferred stock occurs through automatic conversion as a result of initial public offering or post initial public offering trading as discussed above, or as a result of our forcing conversion as described above, or should KCI be sold, the holders would be entitled to receive paid-in-kind dividends as if the preferred stock had remained outstanding through December 31, 2005.
Except as otherwise required by law, the holders of the preferred stock are entitled to vote, on an as-converted basis, together with our common shareholders. KCI, Fremont Partners, L.P., Blum Capital Partners, L.P. and Dr. Leininger, and their affiliates, entered into an Investors' Rights Agreement with the other holders of the preferred stock, which provides for "piggyback" registration rights, restrictions on transfer of the shares of the preferred stock, rights of first offer, "tag-along" rights and "bring-along" rights. Fremont Partners, L.P., Blum Capital Partners, L.P. and Dr. Leininger and their respective affiliates purchased an aggregate of $190.0 million of the preferred stock.
We paid the investors in the preferred stock approximately $5.8 million in arrangement fees. Because the net cash received from the investors related to the preferred stock is approximately $258.0 million and the preferred stock holders are entitled to immediate conversion to common stock for value equal to $263.8 million, a beneficial conversion feature of $5.8 million exists. We have recorded the net proceeds received from the preferred stock holders in equity and have recorded a beneficial conversion feature which has the effect of reducing the preferred stock recorded to $252.2 million. We will accrete through preferred dividends the amount recorded for preferred stock up to its conversion amount over future periods to the redemption date, using the effective interest method. Dividends no longer accrete after twelve years. We also incurred approximately $950,000 in direct and incremental costs related to the preferred stock. We have capitalized these costs and they will be amortized to dividends over 12 years unless the preferred stock is previously converted or redeemed.
After August 11, 2006, the preferred stock dividends may be paid in cash or in kind, at our option. If we opt to pay the dividends in kind, a new beneficial conversion may exist and would be evaluated and recorded at that time.
The terms of our preferred stock restrict us from declaring and paying dividends on our common stock until such time as all outstanding dividends have been paid related to the preferred stock. The preferred stock shall, with respect to the right to receive dividends or distributions of assets and rights upon KCI's liquidation, dissolution or winding up, rank senior to the common stock. The stated value for the preferred stock is equal to the initial stated value together with any accrued dividends through such date that have been added to the stated valued through accretion.
The preferred stock shall be mandatorily redeemed by KCI on the twelfth anniversary of the issue date, subject to two extension periods, which can extend the mandatory redemption date through the seventeenth anniversary of the issue date. The preferred stock must be redeemed for cash, common stock or a combination of cash and common stock, at our option, for fair market value of the common stock along with any cash, equal to the stated value of the preferred stock or the average closing price of the common stock into which such preferred stock is then convertible for the 20 consecutive trading days immediately preceding such redemption. However, such common stock must be listed on a United States national securities exchange or quoted on the NASDAQ stock market and the common stock to be issued in redemption shall not represent more then 35% of the fully diluted common stock of KCI.
Table of Contents(7) EARNINGS (LOSS) PER SHARE
The following table sets forth the reconciliation from basic to diluted average common shares and the calculations of net earnings (loss) per common share. Net earnings (loss) per share was calculated using the weighted average number of common shares outstanding. Common stock equivalents, which consist of stock options and convertible preferred stock, were excluded from the computation of the weighted average number of common shares outstanding in 2003 because their effect was antidilutive. Net earnings (loss) for basic and diluted calculations do not differ (dollars in thousands, except per share data): (See Note 1 (b).)
Three months ended |
Nine months ended |
|||||||
2003 |
2002 |
2003 |
2002 |
|||||
Net earnings (loss) |
$ (34,253) |
$ 9,103 |
$ 1,692 |
$ 29,132 |
||||
Less: Preferred stock dividends, net |
(3,427) |
- |
(3,427) |
- |
||||
______ |
______ |
______ |
______ |
|||||
Net earnings (loss) to common shareholders |
$ (37,680) |
$ 9,103 |
$ (1,735) |
$ 29,132 |
||||
______ |
______ |
______ |
______ |
|||||
Average common shares: |
||||||||
Basic (weighted-average outstanding shares) |
51,139 |
70,928 |
64,398 |
70,927 |
||||
Dilutive potential common shares from stock options (1) |
- |
6,736 |
- |
6,747 |
||||
Dilutive potential common shares from preferred stock |
||||||||
conversion (1) |
- |
- |
- |
- |
||||
______ |
______ |
______ |
______ |
|||||
Diluted (weighted-average outstanding shares) |
51,139 |
77,664 |
64,398 |
77,674 |
||||
______ |
______ |
______ |
______ |
|||||
Basic earnings (loss) per common share |
$ (0.74) |
$ 0.13 |
$ (0.03) |
$ 0.41 |
||||
______ |
______ |
______ |
______ |
|||||
Diluted earnings (loss) per common share |
$ (0.74) |
$ 0.12 |
$ (0.03) |
$ 0.38 |
||||
______ |
______ |
______ |
______ |
(1) Dilutive potential common shares from stock options totaling 6,458 and 5,763 shares and dilutive potential
common shares from preferred stock conversion totaling 8,485 and 2,860 shares have been excluded from the diluted
earnings per share calculation for the three-month and nine-month periods ended September 30, 2003, respectively, due to
their antidilutive effect.
(8) OTHER COMPREHENSIVE INCOME
The components of other comprehensive income are as follows (dollars in thousands):
Three months ended |
|||
2003 |
2002 |
||
Net earnings (loss) |
$ (34,253) |
$ 9,103 |
|
Foreign currency translation adjustment |
1,868 |
39 |
|
Net derivative income (loss), net of taxes of $1,240 in 2003 |
|||
and $34 in 2002 |
(2,302) |
63 |
|
Reclassification adjustment for losses included in |
|||
income, net of taxes of $299 in 2003 and $259 in 2002 |
556 |
482 |
|
Reclassification adjustment for loss recognized on termination |
|||
of interest rate swap, net of taxes of $79 in 2002 |
- |
(147) |
|
______ |
______ |
||
Other comprehensive income |
$ (34,131) |
$ 9,540 |
|
______ |
______ |
Nine months ended |
|||
2003 |
2002 |
||
Net earnings |
$ 1,692 |
$ 29,132 |
|
Foreign currency translation adjustment |
6,944 |
3,531 |
|
Net derivative loss, net of taxes of $1,710 in 2003 |
|||
and $160 in 2002 |
(3,176) |
(298) |
|
Reclassification adjustment for losses included in |
|||
income, net of taxes of $569 in 2003 and $697 in 2002 |
1,057 |
1,295 |
|
Reclassification adjustment for loss recognized on termination |
|||
of interest rate swap, net of taxes of $227 in 2002 |
- |
(405) |
|
______ |
______ |
||
Other comprehensive income |
$ 6,517 |
$ 33,255 |
|
______ |
______ |
The earnings associated with certain of our foreign affiliates are considered to be permanently invested and no provision for U.S. federal and state income taxes on these earnings or translation adjustments has been made.
As of September 30, 2003, derivative financial instruments valued at a liability of $4.6 million were recorded as a result of our adoption of SFAS 133, "Accounting for Derivative Instruments and Hedging Activities." This liability is based upon the valuation of our interest rate protection agreements associated with our new senior credit facility. (See Note 5.)
(9) COMMITMENTS AND CONTINGENCIES
In August 2003, KCI and Wake Forest University filed a lawsuit against BlueSky Medical Corporation and related parties alleging infringement of multiple claims under two Vacuum Assisted Closure ("V.A.C.") patents arising from the manufacturing and marketing of a medical device by BlueSky. KCI and Wake Forest have asserted additional related claims which, together with the infringement claims, we believe are meritorious.
During the fourth quarter of 2002, we recorded a gain from the settlement of an antitrust lawsuit with Hillenbrand Industries, Inc. and its wholly-owned subsidiary, Hill-Rom Company, Inc. Under the settlement, Hillenbrand agreed to pay KCI $250 million in two payments. In January 2003, we received the first installment of $175 million pursuant to the settlement. Net of fees and expenses of $1.7 million, this transaction added $173.3 million of pretax income and $106.4 million of net income to the 2002 fourth quarter results. The cash received, net of approximately $66 million of income taxes and approximately $2 million in fees and expenses, was used to pay down $107 million of indebtedness on the old senior credit facility. Hillenbrand is obligated to pay KCI an additional $75 million in January 2004, subject to certain conditions. No accrual has been made related to this payment.
Other than commitments for new product inventory, including disposable "for sale" products of $16.6 million, we have no material long-term capital commitments.
(10) SEGMENT AND GEOGRAPHIC INFORMATION
We are principally engaged in the rental and sale of innovative therapeutic systems and surfaces throughout the United States and in 15 primary countries internationally.
We define our business segments based on geographic management responsibility. We have two reportable segments: USA, which includes operations in the United States, and International, which includes operations for all international units. We measure segment profit as operating earnings, which is defined as income before interest income or expense, foreign currency gains and losses and income taxes. All intercompany transactions are eliminated in computing revenue, operating earnings and assets. The prior years have been made to conform with
Table of Contentsthe 2003 presentation. Information on segments and a reconciliation of consolidated totals are as follows (dollars in thousands):
Three months ended |
Nine months ended |
||||||
September 30, |
September 30, |
||||||
2003 |
2002 |
2003 |
2002 |
||||
Revenue: |
|||||||
USA |
$ 151,229 |
$ 115,873 |
$ 416,900 |
$ 321,889 |
|||
International |
46,813 |
35,014 |
131,022 |
93,886 |
|||
______ |
_______ |
_______ |
_______ |
||||
Revenue |
$ 198,042 |
$ 150,887 |
$ 547,922 |
$ 415,775 |
|||
______ |
_______ |
_______ |
_______ |
||||
Operating earnings (loss): |
|||||||
USA |
$ 52,919 |
$ 38,685 |
$ 144,654 |
$ 103,824 |
|||
International |
5,264 |
3,607 |
16,368 |
12,255 |
|||
Recapitalization expenses |
(69,955) |
- |
(69,955) |
- |
|||
Other (1): |
|||||||
Executive |
(2,900) |
(2,989) |
(12,239) |
(7,947) |
|||
Finance |
(4,849) |
(4,236) |
(14,773) |
(11,814) |
|||
Manufacturing/Engineering |
(2,186) |
(1,662) |
(4,445) |
(5,321) |
|||
Administration |
(9,477) |
(7,007) |
(21,957) |
(13,897) |
|||
______ |
_______ |
_______ |
_______ |
||||
Total Other |
(19,412) |
(15,894) |
(53,414) |
(38,979) |
|||
______ |
_______ |
_______ |
_______ |
||||
Operating earnings (loss) |
$ (31,184) |
$ 26,398 |
$ 37,653 |
$ 77,100 |
|||
______ |
_______ |
_______ |
_______ |
(11) GUARANTOR CONDENSED CONSOLIDATING FINANCIAL STATEMENTS
On August 11, 2003, we issued and sold an aggregate of $205.0 million principal amount of 7 3/8% Senior Subordinated Notes due 2013.
The notes are guaranteed by each of KCI's direct and indirect 100% owned subsidiaries, other than any entity that is a controlled foreign corporation within the definition of Section 957 of the Internal Revenue code or a holding company whose only assets are investments in a controlled foreign corporation. Each of these subsidiaries is a restricted subsidiary, as defined in the indenture governing the notes. (See Note 5.) We have not presented separate financial statements and other disclosures concerning the subsidiary guarantors because management has determined that such information is not material to investors.
The following tables present the condensed consolidating balance sheets of KCI as a parent company, our guarantor subsidiaries and our non-guarantor subsidiaries as of September 30, 2003 and December 31, 2002 and the related condensed consolidating statements of operations for the three and nine-month periods ended September 30, 2003 and 2002, and the condensed consolidating statements of cash flows for the nine-month periods ended September 30, 2003 and 2002, respectively.
Table of Contents
Condensed Consolidating Guarantor, Non-Guarantor And |
|||||||||
Parent Company Balance Sheet |
|||||||||
September 30, 2003 |
|||||||||
(in thousands) |
|||||||||
(unaudited) |
|||||||||
Kinetic |
|||||||||
Concepts, |
Reclassi- |
Kinetic |
|||||||
Inc. |
Non- |
fications |
Concepts, |
||||||
Parent |
Guarantor |
Guarantor |
and |
Inc. |
|||||
Company |
Sub- |
Sub- |
Elimi- |
and Sub- |
|||||
Borrower |
sidiaries |
sidiaries |
nations |
sidiaries |
|||||
Assets: |
|||||||||
Current assets: |
|||||||||
Cash and cash equivalents |
$ - |
$ 19,495 |
$ 21,633 |
$ - |
$ 41,128 |
||||
Accounts receivable, net |
- |
134,913 |
42,018 |
(6,292) |
170,639 |
||||
Inventories, net |
- |
14,402 |
16,624 |
- |
31,026 |
||||
Prepaid expenses and other current assets |
- |
13,462 |
8,728 |
(5,762) |
16,428 |
||||
_______ |
_______ |
_______ |
_______ |
_______ |
|||||
Total current assets |
- |
182,272 |
89,003 |
(12,054) |
259,221 |
||||
_______ |
_______ |
_______ |
_______ |
_______ |
|||||
Net property, plant and equipment |
- |
106,958 |
38,270 |
(14,056) |
131,172 |
||||
Loan issuance cost, net |
- |
19,385 |
- |
- |
19,385 |
||||
Goodwill |
- |
41,226 |
7,570 |
- |
48,796 |
||||
Other assets, net |
- |
31,551 |
21,661 |
(22,949) |
30,263 |
||||
Intercompany investments and advances |
(324,289) |
678,302 |
9,020 |
(363,033) |
- |
||||
_______ |
_______ |
_______ |
_______ |
_______ |
|||||
|
$ (324,289) |
$1,059,694 |
$ 165,524 |
$ (412,092) |
$ 488,837 |
||||
______ |
______ |
______ |
______ |
______ |
|||||
Liabilities and Share- |
|||||||||
holders' Equity (Deficit): |
|||||||||
Current liabilities: |
|
||||||||
Accounts payable |
$ 37 |
$ 9,430 |
$ 4,376 |
$ - |
$ 13,843 |
||||
Accrued expenses |
135 |
72,558 |
20,096 |
- |
92,789 |
||||
Current installments of long- |
|||||||||
term obligations |
- |
4,950 |
- |
- |
4,950 |
||||
Current installments of capital |
|||||||||
lease obligations |
- |
115 |
- |
- |
115 |
||||
Intercompany payables |
- |
11,169 |
9,180 |
(20,349) |
- |
||||
Income taxes payable |
- |
4,053 |
- |
(4,053) |
- |
||||
_______ |
_______ |
_______ |
_______ |
_______ |
|||||
Total current liabilities |
172 |
102,275 |
33,652 |
(24,402) |
111,697 |
||||
_______ |
_______ |
_______ |
_______ |
_______ |
|||||
Long-term obligations, net of |
|||||||||
current installments |
- |
679,300 |
- |
- |
679,300 |
||||
Capital lease obligations, net of current |
|||||||||
installments |
- |
- |
12 |
- |
12 |
||||
Derivative financial instruments |
- |
4,601 |
- |
- |
4,601 |
||||
Intercompany payables, non current |
- |
(21,500) |
21,500 |
- |
- |
||||
Deferred income taxes, net |
- |
9,683 |
- |
(1,449) |
8,234 |
||||
Deferred gain, sale of headquarters facility |
- |
9,241 |
- |
- |
9,241 |
||||
Other noncurrent liabilities |
- |
21,713 |
- |
(21,500) |
213 |
||||
_______ |
_______ |
_______ |
_______ |
_______ |
|||||
|
172 |
805,313 |
55,164 |
(47,351) |
813,298 |
||||
Preferred stock |
255,655 |
- |
- |
- |
255,655 |
||||
Shareholders' equity (deficit) |
(580,116) |
254,381 |
110,360 |
(364,741) |
(580,116) |
||||
_______ |
_______ |
_______ |
_______ |
_______ |
|||||
|
$ (324,289) |
$1,059,694 |
$ 165,524 |
$ (412,092) |
$ 488,837 |
||||
______ |
______ |
______ |
______ |
______ |
Condensed Consolidating Guarantor, Non-Guarantor And |
|||||||||
Kinetic |
|||||||||
Concepts, |
Reclassi- |
Kinetic |
|||||||
Inc. |
Non- |
fications |
Concepts, |
||||||
Parent |
Guarantor |
Guarantor |
and |
Inc. |
|||||
Company |
Sub- |
Sub- |
Elimi- |
and Sub- |
|||||
Borrower |
sidiaries |
sidiaries |
nations |
sidiaries |
|||||
Assets: |
|||||||||
Current assets: |
|||||||||
Cash and cash equivalents |
$ - |
$ 41,185 |
$ 13,300 |
$ - |
$ 54,485 |
||||
Accounts receivable, net |
- |
125,106 |
35,612 |
(7,822) |
152,896 |
||||
Accounts receivable - other |
175,000 |
- |
- |
- |
175,000 |
||||
Inventories, net |
- |
20,113 |
17,821 |
- |
37,934 |
||||
Prepaid expenses and other |
|||||||||
current assets |
- |
6,377 |
3,383 |
- |
9,760 |
||||
_______ |
_______ |
_______ |
_______ |
_______ |
|||||
Total current assets |
175,000 |
192,781 |
70,116 |
(7,822) |
430,075 |
||||
Net property, plant and equipment |
- |
96,458 |
23,516 |
(14,425) |
105,549 |
||||
Loan issuance cost, net |
- |
5,911 |
- |
- |
5,911 |
||||
Goodwill |
- |
38,724 |
7,633 |
- |
46,357 |
||||
Other assets, net |
- |
31,420 |
20,247 |
(21,500) |
30,167 |
||||
Intercompany investments and advances |
(187,076) |
508,045 |
23,447 |
(344,416) |
- |
||||
_______ |
_______ |
_______ |
_______ |
_______ |
|||||
$ (12,076) |
$ 873,339 |
$ 144,959 |
$ (388,163) |
$ 618,059 |
|||||
______ |
______ |
______ |
______ |
______ |
|||||
Liabilities and Share- |
|||||||||
holders' Equity (Deficit): |
|||||||||
Current liabilities: |
|||||||||
Accounts payable |
$ - |
$ 4,632 |
$ 6,524 |
$ - |
$ 11,156 |
||||
Accrued expenses |
1,522 |
46,058 |
13,976 |
- |
61,556 |
||||
Current installments of long- |
|||||||||
term obligations |
- |
30,550 |
- |
- |
30,550 |
||||
Current installments of capital |
|||||||||
lease obligations |
- |
157 |
- |
- |
157 |
||||
Intercompany payables |
- |
22,497 |
- |
(22,497) |
- |
||||
Derivative financial instruments |
- |
1,341 |
- |
- |
1,341 |
||||
Income taxes payable |
- |
8,615 |
6,000 |
- |
14,615 |
||||
Current deferred income taxes |
66,838 |
- |
- |
- |
66,838 |
||||
_______ |
_______ |
_______ |
_______ |
_______ |
|||||
Total current liabilities |
68,360 |
113,850 |
26,500 |
(22,497) |
186,213 |
||||
_______ |
_______ |
_______ |
_______ |
_______ |
|||||
Long-term obligations, net of |
|||||||||
current installments |
- |
491,300 |
- |
- |
491,300 |
||||
Capital lease obligations, |
|||||||||
net of current installments |
- |
75 |
20 |
- |
95 |
||||
Intercompany payables, noncurrent |
- |
(21,500) |
21,500 |
- |
- |
||||
Deferred income taxes, net |
- |
9,251 |
- |
250 |
9,501 |
||||
Deferred gain, sale of headquarters facility |
- |
10,023 |
- |
- |
10,023 |
||||
Other noncurrent liabilities |
- |
22,863 |
- |
(21,500) |
1,363 |
||||
_______ |
_______ |
_______ |
_______ |
_______ |
|||||
|
68,360 |
625,862 |
48,020 |
(43,747) |
698,495 |
||||
Shareholders' equity (deficit) |
(80,436) |
247,477 |
96,939 |
(344,416) |
(80,436) |
||||
_______ |
_______ |
_______ |
_______ |
_______ |
|||||
|
$ (12,076) |
$ 873,339 |
$ 144,959 |
$ (388,163) |
$ 618,059 |
||||
______ |
______ |
______ |
______ |
______ |
Condensed Consolidating Guarantor, Non-Guarantor And |
|||||||||
Parent Company Statement of Operations |
|||||||||
For the three months ended September 30, 2003 |
|||||||||
(in thousands) |
|||||||||
(unaudited) |
|||||||||
Kinetic |
Historical |
||||||||
Concepts, |
Reclassi- |
Kinetic |
|||||||
Inc. |
Non- |
fications |
Concepts, |
||||||
Parent |
Guarantor |
Guarantor |
and |
Inc. |
|||||
Company |
Sub- |
Sub- |
Elimi- |
and Sub- |
|||||
Borrower |
sidiaries |
sidiaries |
nations |
sidiaries |
|||||
Revenue: |
|||||||||
Rental and service |
$ - |
$ 119,613 |
$ 31,546 |
$ - |
$ 151,159 |
||||
Sales and other |
- |
38,919 |
16,061 |
(8,097) |
46,883 |
||||
______ |
_______ |
______ |
______ |
_______ |
|||||
Total revenue |
- |
158,532 |
47,607 |
(8,097) |
198,042 |
||||
______ |
_______ |
______ |
______ |
_______ |
|||||
Rental expenses |
- |
62,661 |
29,857 |
- |
92,518 |
||||
Cost of goods sold |
- |
17,509 |
5,961 |
(5,418) |
18,052 |
||||
______ |
_______ |
______ |
______ |
_______ |
|||||
Gross profit |
- |
78,362 |
11,789 |
(2,679) |
87,472 |
||||
Selling, general and administrative |
|||||||||
expenses |
- |
43,127 |
5,574 |
- |
48,701 |
||||
Recapitalization expenses |
- |
69,955 |
- |
- |
69,955 |
||||
______ |
_______ |
______ |
______ |
_______ |
|||||
Operating earnings (loss) |
- |
(34,720) |
6,215 |
(2,679) |
(31,184) |
||||
Interest income |
- |
180 |
6 |
- |
186 |
||||
Interest expense |
- |
(25,334) |
(611) |
611 |
(25,334) |
||||
Foreign currency gain |
- |
1,456 |
71 |
- |
1,527 |
||||
______ |
_______ |
______ |
______ |
_______ |
|||||
Earnings (loss) before income |
|||||||||
taxes (benefit) and equity (deficit) in |
|||||||||
earnings of subsidiaries |
- |
(58,418) |
5,681 |
(2,068) |
(54,805) |
||||
Income taxes (benefit) |
- |
(21,997) |
2,221 |
(776) |
(20,552) |
||||
______ |
_______ |
______ |
______ |
_______ |
|||||
Earnings (loss) before equity (deficit) |
|||||||||
in earnings of subsidiaries |
- |
(36,421) |
3,460 |
(1,292) |
(34,253) |
||||
Equity (deficit) in earnings of subsidiaries |
(34,253) |
3,461 |
- |
30,792 |
- |
||||
______ |
_______ |
______ |
______ |
_______ |
|||||
Net earnings (loss) |
$ (34,253) |
$ (32,960) |
$ 3,460 |
$ 29,500 |
$ (34,253) |
||||
______ |
______ |
______ |
______ |
_______ |
Table of Contents
Condensed Consolidating Guarantor, Non-Guarantor And |
|||||||||
Parent Company Statement of Operations |
|||||||||
For the three months ended September 30, 2002 |
|||||||||
(in thousands) |
|||||||||
(unaudited) |
|||||||||
Kinetic |
Historical |
||||||||
Concepts, |
Reclassi- |
Kinetic |
|||||||
Inc. |
Non- |
fications |
Concepts, |
||||||
Parent |
Guarantor |
Guarantor |
and |
Inc. |
|||||
Company |
Sub- |
Sub- |
Elimi- |
and Sub- |
|||||
Borrower |
sidiaries |
sidiaries |
nations |
sidiaries |
|||||
Revenue: |
|||||||||
Rental and service |
$ - |
$ 92,866 |
$ 23,185 |
$ - |
$ 116,051 |
||||
Sales and other |
- |
28,095 |
12,085 |
(5,344) |
34,836 |
||||
_____ |
_______ |
______ |
______ |
_______ |
|||||
Total revenue |
- |
120,961 |
35,270 |
(5,344) |
150,887 |
||||
_____ |
_______ |
______ |
______ |
_______ |
|||||
Rental expenses |
- |
49,821 |
20,451 |
- |
70,272 |
||||
Cost of goods sold |
- |
14,016 |
4,697 |
(3,450) |
15,263 |
||||
_____ |
_______ |
______ |
______ |
_______ |
|||||
Gross profit |
- |
57,124 |
10,122 |
(1,894) |
65,352 |
||||
Selling, general and administrative |
|||||||||
expenses |
- |
35,761 |
3,193 |
- |
38,954 |
||||
_____ |
_______ |
______ |
______ |
_______ |
|||||
Operating earnings |
- |
21,363 |
6,929 |
(1,894) |
26,398 |
||||
Interest income |
- |
112 |
57 |
- |
169 |
||||
Interest expense |
- |
(10,185) |
- |
- |
(10,185) |
||||
Foreign currency loss |
- |
(392) |
(3) |
- |
(395) |
||||
_____ |
_______ |
______ |
______ |
_______ |
|||||
Earnings before income |
|||||||||
taxes and equity in |
|||||||||
earnings of subsidiaries |
- |
10,898 |
6,983 |
(1,894) |
15,987 |
||||
Income taxes |
- |
3,304 |
4,399 |
(819) |
6,884 |
||||
_____ |
_______ |
______ |
______ |
_______ |
|||||
Earnings before equity in |
|||||||||
earnings of subsidiaries |
- |
7,594 |
2,584 |
(1,075) |
9,103 |
||||
Equity in earnings of subsidiaries |
9,103 |
2,584 |
- |
(11,687) |
- |
||||
_____ |
_______ |
______ |
______ |
_______ |
|||||
Net earnings |
$ 9,103 |
$ 10,178 |
$ 2,584 |
$ (12,762) |
$ 9,103 |
||||
_____ |
_______ |
______ |
______ |
_______ |
Table of Contents
Condensed Consolidating Guarantor, Non-Guarantor And |
|||||||||
Parent Company Statement of Operations |
|||||||||
For the nine months ended September 30, 2003 |
|||||||||
(in thousands) |
|||||||||
(unaudited) |
|||||||||
Kinetic |
Historical |
||||||||
Concepts, |
Reclassi- |
Kinetic |
|||||||
Inc. |
Non- |
fications |
Concepts, |
||||||
Parent |
Guarantor |
Guarantor |
and |
Inc. |
|||||
Company |
Sub- |
Sub- |
Elimi- |
and Sub- |
|||||
Borrower |
sidiaries |
sidiaries |
nations |
sidiaries |
|||||
Revenue: |
|||||||||
Rental and service |
$ - |
$ 333,691 |
$ 87,764 |
$ - |
$ 421,455 |
||||
Sales and other |
- |
104,061 |
44,002 |
(21,596) |
126,467 |
||||
______ |
_______ |
______ |
_______ |
_______ |
|||||
Total revenue |
- |
437,752 |
131,766 |
(21,596) |
547,922 |
||||
______ |
_______ |
______ |
_______ |
_______ |
|||||
Rental expenses |
- |
177,643 |
82,165 |
- |
259,808 |
||||
Cost of goods sold |
- |
43,467 |
15,587 |
(12,644) |
46,410 |
||||
______ |
_______ |
______ |
_______ |
_______ |
|||||
Gross profit |
- |
216,642 |
34,014 |
(8,952) |
241,704 |
||||
Selling, general and administrative |
|||||||||
expenses |
- |
119,748 |
14,348 |
- |
134,096 |
||||
Recapitalization expenses |
- |
69,955 |
- |
- |
69,955 |
||||
______ |
_______ |
______ |
_______ |
_______ |
|||||
Operating earnings |
- |
26,939 |
19,666 |
(8,952) |
37,653 |
||||
Interest income |
- |
850 |
83 |
- |
933 |
||||
Interest expense |
- |
(41,562) |
(611) |
611 |
(41,562) |
||||
Foreign currency gain |
- |
5,000 |
683 |
- |
5,683 |
||||
______ |
_______ |
______ |
_______ |
_______ |
|||||
Earnings (loss) before income |
|||||||||
taxes (benefit) and equity in |
|||||||||
earnings of subsidiaries |
- |
(8,773) |
19,821 |
(8,341) |
2,707 |
||||
Income taxes (benefit) |
- |
(1,891) |
6,034 |
(3,128) |
1,015 |
||||
______ |
_______ |
______ |
_______ |
_______ |
|||||
Earnings (loss) before equity in |
|||||||||
earnings of subsidiaries |
- |
(6,882) |
13,787 |
(5,213) |
1,692 |
||||
Equity in earnings of subsidiaries |
1,692 |
13,787 |
- |
(15,479) |
- |
||||
______ |
_______ |
______ |
_______ |
_______ |
|||||
Net earnings |
$ 1,692 |
$ 6,905 |
$ 13,787 |
$ (20,692) |
$ 1,692 |
||||
______ |
_______ |
_____ |
______ |
_______ |
Table of Contents
Condensed Consolidating Guarantor, Non-Guarantor And |
|||||||||
Parent Company Statement of Operations |
|||||||||
For the nine months ended September 30, 2002 |
|||||||||
(in thousands) |
|||||||||
(unaudited) |
|||||||||
Kinetic |
Historical |
||||||||
Concepts, |
Reclassi- |
Kinetic |
|||||||
Inc. |
Non- |
fications |
Concepts, |
||||||
Parent |
Guarantor |
Guarantor |
and |
Inc. |
|||||
Company |
Sub- |
Sub- |
Elimi- |
and Sub- |
|||||
Borrower |
sidiaries |
sidiaries |
nations |
sidiaries |
|||||
Revenue: |
|||||||||
Rental and service |
$ - |
$ 262,373 |
$ 62,688 |
$ - |
$ 325,061 |
||||
Sales and other |
- |
75,421 |
31,823 |
(16,530) |
90,714 |
||||
______ |
_______ |
______ |
______ |
_______ |
|||||
Total revenue |
- |
337,794 |
94,511 |
(16,530) |
415,775 |
||||
______ |
_______ |
______ |
______ |
_______ |
|||||
Rental expenses |
- |
143,443 |
55,883 |
- |
199,326 |
||||
Cost of goods sold |
- |
35,415 |
11,731 |
(10,514) |
36,632 |
||||
______ |
_______ |
______ |
______ |
_______ |
|||||
Gross profit |
- |
158,936 |
26,897 |
(6,016) |
179,817 |
||||
|
|||||||||
Selling, general and administrative |
|||||||||
expenses |
- |
93,865 |
8,852 |
- |
102,717 |
||||
______ |
_______ |
______ |
______ |
_______ |
|||||
Operating earnings |
- |
65,071 |
18,045 |
(6,016) |
77,100 |
||||
Interest income |
- |
133 |
145 |
- |
278 |
||||
Interest expense |
- |
(30,877) |
- |
- |
(30,877) |
||||
Foreign currency gain (loss) |
- |
2,167 |
(114) |
- |
2,053 |
||||
______ |
_______ |
______ |
______ |
_______ |
|||||
Earnings before income |
|||||||||
taxes and equity in |
|||||||||
earnings of subsidiaries |
- |
36,494 |
18,076 |
(6,016) |
48,554 |
||||
Income taxes |
- |
13,645 |
8,183 |
(2,406) |
19,422 |
||||
______ |
_______ |
______ |
______ |
_______ |
|||||
Earnings before equity |
|||||||||
in earnings of subsidiaries |
- |
22,849 |
9,893 |
(3,610) |
29,132 |
||||
Equity in earnings |
|||||||||
of subsidiaries |
29,132 |
9,893 |
- |
(39,025) |
- |
||||
______ |
_______ |
______ |
______ |
_______ |
|||||
Net earnings |
$ 29,132 |
$ 32,742 |
$ 9,893 |
$ (42,635) |
$ 29,132 |
||||
______ |
______ |
______ |
______ |
______ |
Table of Contents
Condensed Consolidating Guarantor, Non-Guarantor And |
|||||||||
Parent Company Statement of Cash Flows |
|||||||||
For the nine months ended September 30, 2003 |
|||||||||
(in thousands) |
|||||||||
(unaudited) |
|||||||||
Kinetic |
|||||||||
Concepts, |
Reclassi- |
Kinetic |
|||||||
Inc. |
Non- |
fications |
Concepts, |
||||||
Parent |
Guarantor |
Guarantor |
and |
Inc. |
|||||
Company |
Sub- |
Sub- |
Elimi- |
and Sub- |
|||||
Borrower |
sidiaries |
sidiaries |
nations |
sidiaries |
|||||
Cash flows from operating activities: |
|||||||||
Net earnings |
$ 1,692 |
$ 6,905 |
$ 13,787 |
$ (20,692) |
$ 1,692 |
||||
Adjustments to reconcile net earnings to net |
|
|
|
|
|
||||
cash provided by operating activities |
105,212 |
34,490 |
(1,827) |
13,450 |
151,325 |
||||
_______ |
_______ |
______ |
______ |
_______ |
|||||
Net cash provided by operating activities |
106,904 |
41,395 |
11,960 |
(7,242) |
153,017 |
||||
_______ |
_______ |
______ |
______ |
_______ |
|||||
Cash flows from investing activities: |
|||||||||
Additions to property, plant and |
|||||||||
equipment |
- |
(30,292) |
(26,497) |
140 |
(56,649) |
||||
Decrease in inventory to be converted into |
|||||||||
equipment for short-term rental |
- |
800 |
- |
- |
800 |
||||
Dispositions of property, plant and |
|||||||||
equipment |
- |
602 |
988 |
- |
1,590 |
||||
Business acquisitions, net of cash |
|||||||||
acquired |
(2,224) |
- |
- |
(2,224) |
|||||
Increase in other assets |
- |
(448) |
(1,351) |
1,448 |
(351) |
||||
_______ |
_______ |
______ |
______ |
_______ |
|||||
Net cash used by investing activities |
- |
(31,562) |
(26,860) |
1,588 |
(56,834) |
||||
_______ |
_______ |
______ |
______ |
_______ |
|||||
Cash flows from financing activities: |
|||||||||
Repayments of notes payable, long-term, |
|||||||||
capital lease and other obligations |
- |
(116,092) |
(8) |
- |
(116,100) |
||||
Proceeds from the exercise of stock options |
903 |
- |
- |
- |
903 |
||||
Recapitalization: |
|||||||||
Payoff of long term debt and bonds |
(408,226) |
- |
- |
(408,226) |
|||||
Proceeds from issuance of new debt and bonds |
685,000 |
- |
- |
685,000 |
|||||
Proceeds from issuance of preferred stock |
258,017 |
- |
- |
- |
258,017 |
||||
Purchase of common stock |
(509,597) |
- |
- |
- |
(509,597) |
||||
Loan issuance costs |
- |
(20,729) |
- |
- |
(20,729) |
||||
Proceeds from (repayments of) |
|||||||||
intercompany investments and advances |
138,949 |
(167,842) |
23,688 |
5,205 |
- |
||||
Other |
4,824 |
(3,634) |
(447) |
(743) |
- |
||||
_______ |
_______ |
______ |
______ |
_______ |
|||||
Net cash provided (used) by financing |
|||||||||
activities |
(106,904) |
(31,523) |
23,233 |
4,462 |
(110,732) |
||||
_______ |
_______ |
______ |
______ |
_______ |
|||||
Effect of exchange rate changes on |
|||||||||
cash and cash equivalents |
- |
- |
- |
1,192 |
1,192 |
||||
_______ |
_______ |
______ |
______ |
_______ |
|||||
Net increase (decrease) in cash and |
|||||||||
cash equivalents |
- |
(21,690) |
8,333 |
- |
(13,357) |
||||
Cash and cash equivalents, |
|||||||||
beginning of period |
- |
41,185 |
13,300 |
- |
54,485 |
||||
_______ |
_______ |
______ |
______ |
_______ |
|||||
Cash and cash equivalents, end |
|||||||||
of period |
$ - |
$ 19,495 |
$ 21,633 |
$ - |
$ 41,128 |
||||
_______ |
_______ |
_____ |
_____ |
______ |
Table of Contents
Condensed Consolidating Guarantor, Non-Guarantor And |
|||||||||
Parent Company Statement of Cash Flows |
|||||||||
For the nine months ended September 30, 2002 |
|||||||||
(in thousands) |
|||||||||
(unaudited) |
|||||||||
Kinetic |
|||||||||
Concepts, |
Reclassi- |
Kinetic |
|||||||
Inc. |
Non- |
fications |
Concepts, |
||||||
Parent |
Guarantor |
Guarantor |
and |
Inc. |
|||||
Company |
Sub- |
Sub- |
Elimi- |
and Sub- |
|||||
Borrower |
sidiaries |
sidiaries |
nations |
sidiaries |
|||||
Cash flows from operating activities: |
|||||||||
Net earnings |
$ 29,132 |
$ 32,742 |
$ 9,893 |
$ (42,635) |
$ 29,132 |
||||
Adjustments to reconcile net earnings |
|
|
|
|
|
||||
to net cash provided by operating activities |
(29,132) |
14,231 |
4,611 |
34,003 |
23,713 |
||||
______ |
______ |
______ |
______ |
______ |
|||||
Net cash provided by operating |
|
|
|
|
|
||||
activities |
- |
46,973 |
14,504 |
(8,632) |
52,845 |
||||
______ |
______ |
______ |
______ |
______ |
|||||
Cash flows from investing activities: |
|||||||||
Additions to property, plant and |
|
|
|
|
|
||||
equipment |
- |
(27,204) |
(17,988) |
1,350 |
(43,842) |
||||
Decrease in inventory to be converted |
|||||||||
into equipment for short-term rental |
- |
2,400 |
- |
- |
2,400 |
||||
Dispositions of property, plant and |
|||||||||
equipment |
- |
1,719 |
879 |
- |
2,598 |
||||
Proceeds from sale of headquarters facility |
17,924 |
- |
- |
17,924 |
|||||
Business acquisitions, net of cash |
|||||||||
acquired |
- |
- |
(3,596) |
- |
(3,596) |
||||
Increase in other assets |
- |
(722) |
(120) |
- |
(842) |
||||
______ |
______ |
______ |
______ |
______ |
|||||
Net cash used by investing |
|||||||||
activities |
- |
(5,883) |
(20,825) |
1,350 |
(25,358) |
||||
______ |
______ |
______ |
______ |
______ |
|||||
Cash flows from financing activities: |
|||||||||
Proceeds from notes payable, long-term, |
|
|
|
|
|
||||
capital lease and other obligations |
- |
16,673 |
27 |
- |
16,700 |
||||
Proceeds from exercise of stock options |
8 |
- |
- |
- |
8 |
||||
Proceeds (borrowings) on intercompany |
|||||||||
investments and advances |
(6,128) |
(17,815) |
6,343 |
17,600 |
- |
||||
Other |
6,120 |
(5,608) |
5,217 |
(5,729) |
- |
||||
______ |
______ |
______ |
______ |
______ |
|||||
Net cash provided (used) by |
|||||||||
financing activities |
- |
(6,750) |
11,587 |
11,871 |
16,708 |
||||
______ |
______ |
______ |
______ |
______ |
|||||
Effect of exchange rate changes on |
|||||||||
cash and cash equivalents |
- |
- |
- |
513 |
513 |
||||
______ |
______ |
______ |
______ |
______ |
|||||
Net increase in cash and |
|||||||||
cash equivalents |
- |
34,340 |
5,266 |
5,102 |
44,708 |
||||
Cash and cash equivalents, |
|||||||||
beginning of period |
- |
- |
5,301 |
(5,102) |
199 |
||||
______ |
______ |
______ |
______ |
______ |
|||||
Cash and cash equivalents, end |
|||||||||
of period |
$ - |
$ 34,340 |
$ 10,567 |
$ - |
$ 44,907 |
||||
______ |
______ |
______ |
______ |
______ |
Table of Contents
This quarterly report on Form 10-Q contains forward-looking statements. When used in this report, the words "estimate," "project," "anticipate," "expect," "intend," "believe" and similar expressions are intended to identify forward-looking statements.
All of the forward-looking statements contained in this report are based on estimates and assumptions made by the management of Kinetic Concepts, Inc. ("KCI," "we," "our" or "us"). These estimates and assumptions reflect our best judgment based on currently known market conditions and other factors. Although we believe such estimates and assumptions to be reasonable, they are inherently uncertain and involve risks and uncertainties beyond our control. In addition, management's assumptions about future events may prove to be inaccurate. Management cautions all readers that the forward-looking statements contained in this report are not guarantees of future performance and we cannot assure any reader that such statements will be realized. In all likelihood, actual results will differ from those contemplated by such forward-looking statements. Any such differences could result from a variety of factors, including the following:
- foreign and domestic economic and business conditions;
- demographic changes;
- government regulations and changes in, or our failure to comply with, government regulations;
- changes in the healthcare reimbursement policies of Medicare Part B or other governmental or
private payers;
- competition;
- the loss of any significant customers;
- restrictions imposed on us due to our significant indebtedness;
- our ability to effectively protect our intellectual property and not infringe on the intellectual
property of others;
- loss of any significant suppliers, especially sole-source suppliers;
- failure of the home care market to continue expanding as we expect;
- failure of V.A.C. therapy to gain home care reimbursement in Europe and other locations;
- any deviation from our expectations for increases in rental and sales volumes for V.A.C. systems
and related disposables during the remainder of 2003;
- any deviation from our expectations of the impact of the recapitalization on our business going forward;
- any deviation from our expectations for increases in future demand for V.A.C. systems;
- liability resulting from litigation; and
- other factors discussed elsewhere in this document and in our filings with the S.E.C.
ITEM 2.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONGeneral
Kinetic Concepts, Inc. is a global medical device company with leadership positions in (1) advanced wound care and (2) therapeutic surfaces which treat and prevent complications resulting from patient immobility. We design, manufacture, market and service a wide range of proprietary products which can significantly improve clinical outcomes while reducing the overall cost of patient care by accelerating the healing process or preventing complications. We have an infrastructure designed to meet the specific needs of medical professionals and patients across all health care settings including acute care hospitals, extended care facilities and patients' homes both in the United States and abroad.
Since the fourth quarter of 2000, our growth has been driven primarily by increased revenue from Vacuum Assisted Closure ("V.A.C.") device rentals and sales, which accounted for approximately 61.9% of total revenue in the first nine months of 2003, up from 52.3% in the first nine months of 2002. We expect V.A.C. growth and the percentage of total revenue from V.A.C. rentals and sales to continue to increase, as it has in each of the last three years. Driven by continued market penetration, increased awareness and the introduction of two new V.A.C. systems in 2002, rental and sales volumes have continued to increase. Revenue for V.A.C. products and related services increased 56.1% from $217.4 million for the nine months ended September 30, 2002 to $339.3 million for the nine months ended September 30, 2003. Both the U.S. and international business segments contributed to this growth.
We have direct operations in the United States, Canada, Europe, Australia and South Africa, and conduct additional business through distributors in Latin America, the Middle East and Asia. We manage our business in two geographical segments, our USA and International divisions. In the United States, which accounted for 76.1% of our revenue for the nine months ended September 30, 2003, we have a substantial presence in all care settings. In the U.S. acute and extended care settings, which accounted for more than half of our revenue, we bill our customers, such as hospitals and extended care facilities, directly. In the U.S. home care setting, where our revenue comes predominantly from V.A.C. products, we provide products and services directly to patients and bill third party payers, such as Medicare and private insurance. Domestic home care revenue is growing faster than the acute or extended care settings. Internationally, substantially all of our revenue is generated from the acute care setting. A small amount of international V.A.C. revenue comes from home care. However, we expect the home care market to increase to the extent that we gain home care reimbursement for V.A.C. therapy with third party payers in Europe and other international locations. Our international operations are subject to foreign currency fluctuations. As a result, we establish and evaluate our business using a constant exchange rate by country. By using a constant exchange rate for comparing our current year activity with prior periods, we effectively eliminate from our operations the variances arising from foreign currency fluctuations. We refer to this internal analysis as revenue and expenses excluding the effects of foreign currency exchange rate fluctuations throughout this report.
For the nine-month period ended September 30, 2003, worldwide V.A.C revenue from the combined acute and extended care settings grew approximately 59% and V.A.C. revenue from the home care setting grew approximately 53% as compared to the nine-month period ended September 30, 2002. The home care market accounted for approximately 44% of V.A.C. business and approximately 27% of our total revenue for the nine-month period ended September 30, 2003. V.A.C. systems used in the home are reimbursed by government insurance, (Medicare and Medicaid) private insurance and managed care organization payers. We have over 150 million member lives under contract with private insurance and managed care organizations.
Table of Contents
Recapitalization
On August 11, 2003, we completed the funding for a leveraged recapitalization of KCI. Prior to the recapitalization, we had $208.2 million of term loans outstanding with varying maturities through 2006, with approximately $58.2 million due in 2004. In addition, our then-existing $50.0 million revolving credit facility was scheduled to expire in late 2003. In order to address the approaching maturities and to take advantage of favorable debt capital markets and interest rates near 50-year historical lows, we entered into a new senior credit facility comprised of a six-year, $100 million revolving credit facility that matures on August 11, 2009 and a seven-year $480 million, term loan facility that matures on August 11, 2010. Due to the additional borrowing capacity to help fund future growth initiatives and the lower cost of capital, we anticipate that the recapitalization will have a positive impact on our business going forward.
The refinancing of our debt in the recapitalization provides us greater financial flexibility and a lower overall cost of capital. Proceeds from the new credit facility, together with $205 million of 7 3/8% Senior Subordinated Notes due 2013 and $263.8 million of preferred stock were used to retire all of our previously existing debt, to repurchase a portion of our outstanding common stock and vested stock options, and to pay fees and expenses associated with the recapitalization.
Our September 30, 2003, three-month and nine-month results reflect the impact of the recapitalization including a charge to earnings of $86.3 million before tax benefits related to the recapitalization of $32.3 million. The charge to earnings, pretax, included a $67.5 million charge to compensation expense for the repurchase, or cash settlement, of vested options, together with $11.1 million in expenses for the payment of a consent fee and an early redemption premium related to the redemption of the 9 5/8% Senior Subordinated Notes due 2007. Additionally, we wrote off debt issuance costs related to our old senior credit facility and the 9 5/8% Senior Subordinated Notes due 2007 totaling approximately $5.2 million, pretax. The remaining expenses of approximately $2.5 million, pretax, were related to miscellaneous fees and expenses associated with the share repurchase. (See Note 2 of Notes to Condensed Consolidated Financial Statements for a further di scussion of the recapitalization.)
Table of Contents
Non-GAAP Financial Information:
Throughout this report, we have presented income statement items on a non-GAAP basis to exclude the impact of the recapitalization completed in the third quarter of 2003 on the three-month period ended September 30, 2003. These non-GAAP financial measures do not replace the presentation of our GAAP financial results. We have provided this supplemental non-GAAP information because it provides meaningful information regarding our results on a consistent and comparable basis for the periods presented. Management uses this non-GAAP financial information for reviewing the operating results of its business segments and for analyzing potential future business trends in connection with its budget process. In addition, we believe investors utilize this information to evaluate period-to-period results and to understand potential future operating results. The following schedules detail the effect of the recapitalization on the 2003 results (dollars in thousands):
Three months ended September 30, 2003 |
|||||||
Percent |
|||||||
Excluding |
To |
||||||
As reported |
Recapitalization |
Recapitalization |
Revenue |
||||
Total revenue |
$ 198,042 |
$ - |
$198,042 |
100.0% |
|||
Rental expenses |
92,518 |
- |
92,518 |
||||
Cost of goods sold |
18,052 |
- |
18,052 |
||||
_______ |
_______ |
______ |
|||||
Gross profit |
87,472 |
- |
87,472 |
44.2% |
|||
Selling, general and |
|||||||
administrative expenses |
48,701 |
- |
48,701 |
||||
Recapitalization expenses |
69,955 |
69,955 |
- |
||||
_______ |
_______ |
______ |
|||||
Operating earnings (loss) |
(31,184) |
(69,955) |
38,771 |
19.6% |
|||
Interest income |
186 |
- |
186 |
||||
Interest expense |
(25,334) |
(16,302) |
(9,032) |
||||
Foreign currency gain |
1,527 |
- |
1,527 |
||||
_______ |
_______ |
______ |
|||||
Earnings (loss) before income |
|||||||
taxes (benefit) |
(54,805) |
(86,257) |
31,452 |
||||
Income taxes (benefit) |
(20,552) |
(32,346) |
11,794 |
||||
_______ |
_______ |
______ |
|||||
Net earnings (loss) |
$ (34,253) |
$ (53,911) |
$ 19,658 |
9.9% |
|||
_______ |
________ |
______ |
Nine months ended September 30, 2003 |
|||||||
Percent |
|||||||
Excluding |
To |
||||||
As reported |
Recapitalization |
Recapitalization |
Revenue |
||||
Total revenue |
$ 547,922 |
$ - |
$ 547,922 |
100.0% |
|||
|
|||||||
Rental expenses |
259,808 |
- |
259,808 |
||||
Cost of goods sold |
46,410 |
- |
46,410 |
||||
_______ |
_______ |
_______ |
|||||
Gross profit |
241,704 |
- |
241,704 |
44.1% |
|||
|
|||||||
Selling, general and |
|||||||
administrative expenses |
134,096 |
- |
134,096 |
||||
Recapitalization expenses |
69,955 |
69,955 |
- |
||||
_______ |
_______ |
_______ |
|||||
Operating earnings (loss) |
37,653 |
(69,955) |
107,608 |
19.6% |
|||
|
|||||||
Interest income |
933 |
- |
933 |
||||
Interest expense |
(41,562) |
(16,302) |
(25,260) |
||||
Foreign currency gain |
5,683 |
- |
5,683 |
||||
_______ |
_______ |
_______ |
|||||
Earnings (loss) before income |
|||||||
taxes (benefit) |
2,707 |
(86,257) |
88,964 |
||||
Income taxes (benefit) |
1,015 |
(32,346) |
33,361 |
||||
_______ |
_______ |
_______ |
|||||
Net earnings (loss) |
$ 1,692 |
$ (53,911) |
$ 55,603 |
10.1% |
|||
_______ |
_______ |
_______ |
Results of Operations
Third Quarter of 2003 Compared to Third Quarter of 2002
The following table sets forth, for the periods indicated, the percentage relationship of each item to total revenue as well as the change in each line item as compared to the third quarter of the prior year (dollars in thousands):
Three months ended September 30, |
||||||||
Revenue Relationship |
Variance |
|||||||
2003 |
2002 |
Dollars |
Percent |
|||||
Revenue: |
||||||||
Rental and service |
76 |
% |
77 |
% |
$ 35,108 |
30 |
% |
|
Sales and other |
24 |
23 |
12,047 |
35 |
||||
___ |
___ |
______ |
||||||
Total revenue |
100 |
100 |
47,155 |
31 |
||||
Rental expenses |
47 |
46 |
22,246 |
32 |
||||
Cost of goods sold |
9 |
10 |
2,789 |
18 |
||||
___ |
___ |
______ |
||||||
Gross profit |
44 |
44 |
22,120 |
34 |
||||
Selling, general and administrative |
||||||||
expenses |
25 |
26 |
9,747 |
25 |
||||
Recapitalization expenses |
35 |
- |
69,955 |
- |
||||
___ |
___ |
______ |
||||||
Operating earnings (loss) |
(16) |
18 |
(57,582) |
- |
||||
Interest income |
- |
|
- |
|
17 |
10 |
||
Interest expense |
(13) |
(7) |
(15,149) |
- |
||||
Foreign currency gain (loss) |
1 |
- |
1,922 |
487 |
||||
___ |
___ |
______ |
||||||
Earnings before income taxes (benefit) |
(28) |
11 |
(70,792) |
- |
||||
Income taxes (benefit) |
(11) |
5 |
(27,436) |
- |
||||
___ |
___ |
______ |
||||||
Net earnings (loss) |
(17) |
% |
6 |
% |
$ (43,356) |
- |
% |
|
___ |
___ |
_____ |
Table of Contents
Total Revenue:
Our revenue is divided between two primary operating segments: USA and International. The following table sets forth, for the periods indicated, the amount of revenue derived from each of these segments (dollars in thousands):
Three months ended September 30, |
||||||||||
Variance |
||||||||||
2003 |
2002 |
Dollars |
Percent |
|||||||
USA |
||||||||||
V.A.C. |
||||||||||
Rental |
$ 82,958 |
$ 55,945 |
$ 27,013 |
48.3 |
% |
|||||
Sales |
22,903 |
15,185 |
7,718 |
50.8 |
||||||
_______ |
_______ |
______ |
||||||||
105,861 |
71,130 |
34,731 |
48.8 |
|||||||
Therapeutic surfaces/other |
||||||||||
Rental |
37,297 |
37,127 |
170 |
0.5 |
||||||
Sales |
8,071 |
7,616 |
455 |
6.0 |
||||||
_______ |
_______ |
______ |
||||||||
Total therapeutic surfaces/other |
45,368 |
44,743 |
625 |
1.4 |
||||||
Total USA rental |
120,255 |
93,072 |
27,183 |
29.2 |
||||||
Total USA sales |
30,974 |
22,801 |
8,173 |
35.8 |
||||||
_______ |
_______ |
______ |
||||||||
Subtotal - USA |
$ 151,229 |
$ 115,873 |
$ 35,356 |
30.5 |
% |
|||||
_______ |
_______ |
______ |
||||||||
International |
||||||||||
V.A.C. |
||||||||||
Rental |
$ 11,087 |
$ 6,163 |
$ 4,924 |
79.9 |
% |
|||||
Sales |
10,694 |
6,393 |
4,301 |
67.3 |
||||||
_______ |
_______ |
______ |
||||||||
Total V.A.C. |
21,781 |
12,556 |
9,225 |
73.5 |
||||||
Therapeutic surfaces/other |
||||||||||
Rental |
19,817 |
16,816 |
3,001 |
17.8 |
||||||
Sales |
5,215 |
5,642 |
(427) |
(7.6) |
||||||
_______ |
_______ |
______ |
||||||||
Total therapeutic surfaces/other |
25,032 |
22,458 |
2,574 |
11.5 |
||||||
Total International rental |
30,904 |
22,979 |
7,925 |
34.5 |
||||||
Total International sales |
15,909 |
12,035 |
3,874 |
32.2 |
||||||
_______ |
_______ |
______ |
||||||||
Subtotal - International |
$ 46,813 |
$ 35,014 |
$ 11,799 |
33.7 |
% |
|||||
_______ |
_______ |
______ |
||||||||
Total revenue |
$ 198,042 |
$ 150,887 |
$ 47,155 |
31.3 |
% |
|||||
_______ |
_______ |
______ |
Total revenue in the third quarter of 2003 increased $47.2 million, or 31.3%, from the prior-year period due primarily to increased rental and sales volumes for V.A.C. systems and related disposables resulting from increased market penetration and product awareness. Rental revenue increased $35.1 million, or 30.3%, from the third quarter of 2002 while sales revenue increased $12.0 million, or 34.6%, compared to the prior-year period.
Total domestic revenue for the third quarter of 2003 increased $35.4 million, or 30.5%, from the prior-year quarter due directly to increased V.A.C. rentals and sales. Domestic rental revenue in the third quarter of 2003 increased $27.2 million, or 29.2%, from the prior-year period and domestic sales revenue in the third quarter of 2003 increased $8.2 million, or 35.8%, from a year ago. The increases in total domestic rental and sales revenue are due to increased V.A.C. rental volumes which resulted in increased demand for associated disposables, partially offset by a 21.6% decrease in sales revenue from vascular products and a 11.4% decrease in surface rentals in the extended
Table of Contentscare market. For the third quarter of 2003, average V.A.C. units out on rent increased 11.2% as compared to the second quarter of 2003 and increased 50.1% from the third quarter of 2002. Average rental price for the third quarter of 2003 was down approximately 1.0% compared with both the second quarter of 2003 and the third quarter of 2002.
Domestic V.A.C. revenue increased in the third quarter of 2003 by $34.7 million, or 48.8%, from the prior-year quarter due to an increase of rental and sales volumes resulting from increased market penetration and product awareness. Revenue from V.A.C. rentals increased $27.0 million, or 48.3%, from the prior-year quarter. The increased rental revenue resulted from an increase in average units on rent per month of 50.1% for the third quarter, which was partially offset by a 1.2% decline in average rental price. Some managed care organizations pay an all-inclusive daily rate, which covers the rental of V.A.C. systems and all needed disposables. All revenue associated with all-inclusive pricing is included in rental revenue. We are experiencing a shift away from all-inclusive pricing in the home care setting with third party payers. As we contract with these third party payers, our contracts are providing separate pricing for rental and disposable sa le products versus the all-inclusive pricing previously used. Therefore, we have experienced, and expect to continue experiencing, a shift in revenue between the rental classification and the sales classification. V.A.C. sales increased in the third quarter of 2003 by $7.7 million, or 50.8%, from the prior-year quarter due to the shift in pricing methodology discussed above along with increased demand for V.A.C. disposables associated with increased V.A.C systems rentals. The cost of V.A.C. disposables, whether purchased through all-inclusive pricing or by itemized sale, is included in cost of goods sold.
Domestic therapeutic surfaces/other revenue of $45.4 million for the third quarter of 2003 increased $625,000, or 1.4%, from the prior-year quarter. Rental revenue from therapeutic surfaces/other remained materially unchanged when compared to the prior-year quarter as higher blended unit pricing of 6.6% in the acute, extended and home care markets was offset by a 16.6% lower unit volume in the combined extended and home care markets. Sales revenue from vascular devices and dressings was down approximately $480,000, or 21.6%. The following table sets forth, for the periods indicated, the amount of total rental and sales revenue derived from each of our domestic care settings (dollars in thousands):
Three months ended September 30, |
||||
Variance |
||||
2003 |
2002 |
Dollars |
Percent |
|
Acute/extended surfaces |
$ 40,558 |
$ 39,586 |
$ 972 |
2.5 % |
Home surfaces |
2,501 |
2,341 |
160 |
6.8 |
Vascular-compression therapy |
1,891 |
2,417 |
(526) |
(21.8) |
Other |
418 |
399 |
19 |
4.8 |
______ |
______ |
____ |
||
Total |
$ 45,368 |
$ 44,743 |
$ 625 |
1.4 % |
______ |
______ |
____ |
The majority of our therapeutic surfaces/other business is generated in the hospital, or acute care, setting. Average acute care rental therapeutic surface units on rent per month decreased 1.1% compared to the prior-year period, while average pricing increased 3.4% due primarily to product mix changes. Our acute care revenue is fueled by growth in our bariatric line. Extended care rental units decreased 16.9% due to lower overall Medicare Part A reimbursement in nursing homes and continued local and regional competition for our lower-therapy products. Extended care surface rental price improved 6.6% over the prior-year period on average. Home care therapeutic surface revenue increased 6.8% from the prior-year period due to a change in our revenue mix. We experienced increased sales of lower-therapy wound care therapeutic surface units, which, in turn, decreased the rental of therapeutic surfaces in the home care setting. Overall, the average numb er of domestic therapeutic surface rental units per month for the third quarter of 2003 declined 5.6% as compared to the prior period, but this decline was offset by a 6.6% price increase resulting from changes in our product mix. Our vascular business is declining due to a 38.1% decline in unit sales.
Table of ContentsRevenue from our international operating unit for the third quarter of 2003 increased $11.8 million, or 33.7%, over the prior-year period. Favorable foreign currency exchange movements accounted for $5.2 million of the total international revenue increase when compared to the prior-year quarter. The majority of our international revenue is generated in the acute care
setting. International rental revenue increased $7.9 million, or 34.5%, from the prior-year period and sales revenue was up $3.9 million, or 32.2%, compared to the prior-year quarter. Excluding the effects of foreign currency exchange rate fluctuations, total international revenue increased $6.6 million, or 18.7%, from the prior-year period, rental revenue increased $4.5 million, or 19.3%, and sales revenue increased $2.1 million, or 17.6%. The rental revenue increase reflects a 49.7% increase in V.A.C. systems out on rent alon g with a 7.6% increase in therapeutic surface rental units on rent, primarily in overlays. We also experienced improved rental pricing for our V.A.C. systems for the three months ended September 30, 2003 as compared to the same period of the prior year. International surfaces revenue for the 2003 quarter was $25.0 million, a $2.6 million, or 11.5%, increase from a year ago. Therapeutic surfaces rental pricing remained essentially unchanged as compared to the prior-year period. The international sales increase was due to increased demand for V.A.C. systems and related disposables.Rental Expenses: Rental, or "field," expenses of $92.5 million for the third quarter of 2003 increased $22.2 million, or 31.7%, from $70.3 million in the prior-year period. Rental expense is variable and fluctuates with revenue. The field expense increase was directly associated with the growth in V.A.C. revenue, such as increased product licensing expenses of $5.2 million, labor of $7.1 million, marketing expenses of $2.3 million, incentive compensation of $2.2 million, rental equipment depreciation of $1.9 million and parts expense of approximately $826,000. Of the $22.2 million variance in rental expenses for the third quarter of 2003, approximately $4.4 million resulted from foreign currency exchange rate fluctuations. Field expenses for the third quarter of 2003 represented 61.2% of total rental revenue compared to 60.6% in the prior-year quarter.
Cost of Goods Sold: Cost of goods sold of $18.1 million in the third quarter of 2003 increased $2.8 million, or 18.3%, from $15.3 million in the prior-year period due to increased sales of V.A.C. disposables. Sales margins increased to 61.5% in the third quarter of 2003 as compared to 56.2% in the prior-year period due to the shift away from all-inclusive pricing arrangements discussed above and cost reductions resulting from favorable pricing in our global supply contract for V.A.C. disposables entered into in December 2002.
Gross Profit: Gross profit in the third quarter of 2003 increased $22.1 million, or 33.8%, to $87.5 million from $65.4 million in the prior-year quarter due primarily to the quarter-to-quarter increase in revenue resulting from increased demand for V.A.C. systems and related disposables. Gross profit margin in the third quarter of 2003 was 44.2%, up from 43.3% in the prior-year quarter due primarily to the increase in revenue discussed above.
Selling, General and Administrative Expenses: Selling, general and administrative expenses increased $9.7 million, or 25.0%, to $48.7 million in the third quarter of 2003 from $39.0 million in the prior-year quarter. This $9.7 million variance includes higher administrative costs of $3.4 million associated with hiring of additional personnel for our national call center and billing collections departments, division labor and incentive compensation of $1.2 million and product licensing expense of $1.0 million. Additionally, engineering and manufacturing costs increased $1.7 million from the prior-year quarter. As a percentage of total revenue, selling, general and administrative expenses decreased to 24.6% in the third quarter of 2003 as compared to 25.8% in the prior-year quarter.
Recapitalization Expenses: During the third quarter of 2003, we recognized $70.0 million, in fees and expenses, excluding $16.3 million charged to interest expense, resulting from the transactions associated with the recapitalization. (See Note 2 of Notes to Condensed Consolidated Financial Statements.)
Table of ContentsOperating Earnings:
Operating earnings for the third quarter of 2003 decreased $57.6 million, or 218.1%, to a loss of $31.2 million compared to $26.4 million in the same period in 2002 primarily due to expenses of $70.0 million recorded related to the recapitalization. Excluding recapitalization expenses, operating earnings would have increased $12.4 million over the prior year period, or 46.9%, to $38.8 million. This increase in operating earnings was directly attributable to the increase in revenue for the period, partially offset by higher operating costs and expenses. Operating margins for the third quarter of 2003, excluding recapitalization expenses, would have been 19.6%, up from 17.5% in the prior-year quarter, due to the increase in revenue.Non-GAAP Financial Information: We use earnings before interest, taxes, depreciation and amortization ("EBITDA") as a measure of leverage capacity and debt service ability. We consider EBITDA to be a key liquidity measure but it should not be considered as a measure of financial performance under GAAP or as an acceptable alternative to GAAP cash flows from operating activities, net income or operating income. Management uses this non-GAAP financial information to measure liquidity and we believe investors use the information for the same purpose. We have provided this supplemental non-GAAP information to demonstrate meaningful information regarding our liquidity on a consistent and comparable basis for the periods presented. Our definition of EBITDA is not necessarily comparable to similarly titled measures reported by other companies and is not the same as that term is used under our new senior credit agreement. The following table presents a reconciliation of EBITD A to cash flow from operating activities.
Three months ended September 30, |
|||
2003 |
2002 |
||
Net earnings (loss) |
$ (34,253) |
$ 9,103 |
|
Income tax expense (benefit) |
(20,552) |
6,884 |
|
Interest expense (1) |
25,334 |
10,185 |
|
Depreciation |
11,699 |
8,690 |
|
Amortization (2) |
175 |
127 |
|
______ |
______ |
||
EBITDA (3) |
(17,597) |
34,989 |
|
Provision for uncollectible accounts receivable |
1,605 |
2,085 |
|
Amortization of deferred gain/leaseback on |
|||
headquarters facility |
(261) |
(171) |
|
Write-off of deferred loan fees |
5,233 |
- |
|
Non-cash accrual-recapitalization expenses |
8,907 |
- |
|
Non-cash amortization-stock award to directors |
92 |
- |
|
Amortization of loan issuance costs |
626 |
579 |
|
Income tax benefit (expense) |
20,552 |
(6,884) |
|
Interest expense (1) |
(25,334) |
(10,185) |
|
Change in assets and liabilities net of effects |
|||
from purchase of subsidiaries and |
|||
recapitalization expenses |
(39,511) |
8,505 |
|
______ |
______ |
||
Net cash provided (used) by operating activities |
$ (45,688) |
$ 28,918 |
|
______ |
______ |
(1) Amounts for 2003 include an aggregate of $16,302 in expense for the redemption premium and consent fee
paid in connection with the redemption of our 9 5/8% Senior Subordinated Notes due 2007
combined with the write off of unamortized loan issuance costs associated with the previous
senior credit facility.
(2) Net of amortization of loan issuance costs, which is included in interest expense.
(3) 2003 includes recapitalization expenses of $70.0 million.
Interest Expense:
Interest expense in the third quarter of 2003 was $25.3 million compared to $10.2 million in the prior-year quarter. This increase is primarily due to expenses related to the recapitalization completed in the third quarter of 2003. Excluding recapitalization expenses, interest expense would have decreased $1.2 million, or 11.3%, to $9.0 million in the third quarter of 2003. This decrease was due primarily to the partial paydown on our previously existing credit facility resulting from the $175 million antitrust settlement payment received in January 2003 and lower interest rates on our new senior credit facility and new subordinated notes. (See Notes 2, 5 and 9 of Notes to Condensed Consolidated Financial Statements.)Net Earnings (Loss): A net loss of $34.3 million was recorded in the third quarter of 2003 as compared to net earnings of $9.1 million in the prior-year period due primarily due to the expenses recorded related to the recapitalization. Excluding recapitalization expenses, net earnings would have increased by $10.6 million, or 116.0%, to $19.7 million due to the increase in operating earnings discussed above. Effective tax rates for the third quarter of 2003 and 2002 were 37.5% and 43.1%, respectively.
Results of Operations
First Nine Months of 2003 Compared to First Nine Months of 2002
The following table sets forth, for the periods indicated, the percentage relationship of each item to total revenue as well as the change in each line item as compared to the first nine months of the prior year (dollars in thousands):
Nine months ended September 30, |
||||||||
Revenue Relationship |
Variance |
|||||||
2003 |
|
2002 |
Dollars |
Percent |
||||
Revenue: |
||||||||
Rental and service |
77 |
% |
78 |
% |
$ 96,394 |
30 |
% |
|
Sales and other |
23 |
22 |
35,753 |
39 |
||||
___ |
___ |
______ |
||||||
Total revenue |
100 |
100 |
132,147 |
32 |
||||
Rental expenses |
47 |
48 |
60,482 |
30 |
||||
Cost of goods sold |
9 |
9 |
9,778 |
27 |
||||
___ |
___ |
______ |
||||||
Gross profit |
44 |
43 |
61,887 |
34 |
||||
Selling, general and administrative |
||||||||
expenses |
24 |
24 |
31,379 |
31 |
||||
Recapitalization expenses |
13 |
- |
69,955 |
- |
||||
___ |
___ |
______ |
||||||
Operating earnings |
7 |
19 |
(39,447) |
- |
||||
Interest income |
- |
|
- |
|
655 |
236 |
||
Interest expense |
(8) |
(7) |
(10,685) |
- |
||||
Foreign currency gain |
1 |
- |
3,630 |
177 |
||||
___ |
___ |
______ |
||||||
Earnings before income taxes |
- |
12 |
(45,847) |
- |
||||
Income taxes |
- |
5 |
(18,407) |
- |
||||
___ |
___ |
______ |
||||||
Net earnings |
- |
% |
7 |
% |
$ (27,440) |
- |
% |
|
___ |
___ |
_____ |
Table of Contents
Total Revenue:
Our revenue is divided between two primary operating segments: USA and International. The following table sets forth, for the periods indicated, the amount of revenue derived from each of these segments (dollars in thousands):
Nine months ended September 30, |
|||||||||||
Variance |
|||||||||||
2003 |
2002 |
Dollars |
Percent |
||||||||
USA |
|||||||||||
V.A.C. |
|||||||||||
Rental |
$ 222,801 |
$ 150,154 |
$ 72,647 |
48.4 |
% |
||||||
Sales |
59,850 |
36,887 |
22,963 |
62.3 |
|||||||
_______ |
_______ |
_______ |
|||||||||
Total V.A.C. |
282,651 |
187,041 |
95,610 |
51.1 |
|||||||
Therapeutic surfaces/other |
|||||||||||
Rental |
111,532 |
112,745 |
(1,213) |
(1.1) |
|||||||
Sales |
22,717 |
22,103 |
614 |
2.8 |
|||||||
_______ |
_______ |
_______ |
|||||||||
Total therapeutic surfaces/other |
134,249 |
134,848 |
(599) |
(0.4) |
|||||||
Total USA rental |
334,333 |
262,899 |
71,434 |
27.2 |
|||||||
Total USA sales |
82,567 |
58,990 |
23,577 |
40.0 |
|||||||
_______ |
_______ |
_______ |
|||||||||
Subtotal - USA |
$ 416,900 |
$ 321,889 |
$ 95,011 |
29.5 |
% |
||||||
_______ |
_______ |
_______ |
|||||||||
International |
|||||||||||
V.A.C. |
|||||||||||
Rental |
$ 28,747 |
$ 14,370 |
$ 14,377 |
100.0 |
% |
||||||
Sales |
27,881 |
16,004 |
11,877 |
74.2 |
|||||||
_______ |
_______ |
_______ |
|||||||||
Total V.A.C. |
56,628 |
30,374 |
26,254 |
86.4 |
|||||||
Therapeutic surfaces/other |
|||||||||||
Rental |
58,375 |
47,792 |
10,583 |
22.1 |
|||||||
Sales |
16,019 |
15,720 |
299 |
1.9 |
|||||||
_______ |
_______ |
_______ |
|||||||||
Total therapeutic surfaces/other |
74,394 |
63,512 |
10,882 |
17.1 |
|||||||
Total International rental |
87,122 |
62,162 |
24,960 |
40.2 |
|||||||
Total International sales |
43,900 |
31,724 |
12,176 |
38.4 |
|||||||
_______ |
_______ |
_______ |
|||||||||
Subtotal - International |
$ 131,022 |
$ 93,886 |
$ 37,136 |
39.6 |
% |
||||||
_______ |
_______ |
_______ |
|||||||||
Total revenue |
$ 547,922 |
$ 415,775 |
$ 132,147 |
31.8 |
% |
||||||
_______ |
_______ |
_______ |
Total revenue in the first nine months of 2003 increased $132.1 million, or 31.8%, from the prior-year period due primarily to increased rental and sales volumes for V.A.C. systems and related disposables resulting from increased market penetration and product awareness. Rental revenue increased $96.4 million, or 29.7%, from the first nine months of 2002 due primarily to higher unit demand for the V.A.C. Sales revenue for the nine-month period increased approximately $35.7 million, or 39.4%, compared to the prior-year period due primarily to increased sales volumes of V.A.C. disposables, partially offset by $1.8 million lower sales of vascular products. Table of Contents
Total domestic revenue for the first nine months of 2003 increased $95.0 million, or 29.5%, from the prior-year period due directly to increased V.A.C. rentals and sales. Domestic rental revenue in the first nine months of 2003 increased $71.4 million, or 27.2%, from the prior-year period and domestic sales revenue in the first nine months of 2003 increased $23.6 million, or 40.0%, from the prior-year period. The increases in total domestic rental and sales revenue are due to increased V.A.C. rental volumes which resulted in increased demand for associated disposables, partially offset by a 25.4% decrease in sales revenue from vascular products and a 11.4% decrease in surface rentals in the extended care market. For the nine-month period ended September 30, 2003, average V.A.C. units out on rent increased 50.6% as compared to the same period a year ago.
Domestic V.A.C. revenue increased in the first nine months of 2003 by $95.6 million, or 51.1%, from the prior-year period due to an increase of rental and sales volumes resulting from increased market penetration and product awareness. Revenue from V.A.C. rentals increased $72.6 million, or 48.4%, from the prior-year period. The increased rental revenue resulted from an increase in average units on rent per month of 50.6% for the nine-month period, which was partially offset by a 1.5% decline in average rental price. Some managed care organizations pay an all-inclusive daily rate, which covers the rental of V.A.C. systems and all needed disposables. All revenue associated with all-inclusive pricing is included in rental revenue. We are experiencing a shift away from all-inclusive pricing in the home care setting with third party payers. As we contract with these third party payers, our contracts are providing separate pricing for rental and disposa ble sale products versus the all-inclusive pricing previously used. Therefore, we have experienced, and expect to continue experiencing, a shift in revenue between the rental classification and the sales classification. V.A.C. sales increased in the first nine months of 2003 by $23.0 million, or 62.3%, from the prior-year period due to the shift in pricing methodology discussed above along with increased demand for V.A.C. disposables associated with increased V.A.C. systems rentals. The cost of V.A.C. disposables, whether purchased through all-inclusive pricing or by itemized sale, is included in cost of goods sold.
Domestic therapeutic surfaces/other revenue of $134.2 million for the nine-month period ended September 30, 2003 decreased approximately $600,000, or 0.4%, from the prior-year period. Rental revenue from therapeutic surfaces/other remained materially unchanged when compared to the prior-year period as higher blended unit pricing of 4.9% in the acute, extended and home care markets was offset by an 18.1% lower unit volume in the combined extended and home care markets. Sales revenue from vascular devices and dressings was down $1.8 million, or 25.4%. The following table sets forth, for the periods indicated, the amount of total rental and sales revenue derived from each of our domestic care settings (dollars in thousands):
Nine months ended September 30, |
||||
Variance |
||||
2003 |
2002 |
Dollars |
Percent |
|
Acute/extended surfaces |
$ 119,744 |
$ 119,164 |
$ 580 |
0.5 % |
Home surfaces |
7,515 |
7,061 |
454 |
6.4 |
Vascular-compression therapy |
5,741 |
7,585 |
(1,844) |
(24.3) |
Other |
1,249 |
1,038 |
211 |
20.3 |
______ |
______ |
_____ |
||
Total |
$ 134,249 |
$ 134,848 |
$ (599) |
(0.4)% |
______ |
______ |
_____ |
The majority of our therapeutic surfaces/other business is generated in the hospital, or acute care, setting. Average acute care rental therapeutic surface units on rent per month remained essentially unchanged compared to the prior-year period, while average pricing increased 1.8% due primarily to product mix changes. Our acute care revenue is fueled by growth in our bariatric line. Extended care rental units decreased 17.6% due to lower overall Medicare Part A reimbursement in nursing homes and continued local and regional competition for our lower-therapy products. Extended care surface rental pricing improved 7.6% over the prior year on average. Home care therapeutic surface revenue increased 6.4% from the prior-year period due to a change in our revenue mix. We experienced increased sales of lower-therapy wound care therapeutic surface units, which, in turn, decreased the rental of therapeutic surfaces in the home care setting. Overall, the a verage number of domestic therapeutic surface
Table of Contentsrental units per month for the first nine months of 2003 declined 5.7% as compared to the prior-year period, but this decline was offset by a 4.9% price increase resulting from changes in our product mix. Our vascular business is declining due to a 25.6% decline in unit sales.
Revenue from our international operating unit for the first nine months of 2003 increased $37.1 million, or 39.6%, over the prior-year period. Favorable foreign currency exchange movements accounted for $16.7 million of the total international revenue increase when compared to the prior year period. The majority of our international revenue is generated in the acute care setting. International rental revenue increased $25.0 million, or 40.2%, from the prior-year period and sales revenue was up $12.2 million, or 38.4%, compared to the prior year. Excluding the effects of foreign currency exchange rate fluctuations, total international revenue increased $20.4 million, or 20.7%, from the prior-year period, rental revenue increased $13.7 million, or 21.0%, and sales revenue increased $6.7 million, or 20.2%. The rental revenue increase reflects a 55.3% increase in V.A.C. systems out on rent along with a 6.0% increase in therapeutic surface rental units o n rent, primarily in overlays. We also experienced improved rental pricing for our V.A.C. systems for the nine months ended September 30, 2003 as compared to the same period in the prior year. International surfaces revenue for the first nine months of 2003 was $74.4 million, a $10.9 million, or 17.1%, increase from a year ago. Therapeutic surfaces rental pricings remained essentially unchanged as compared to the prior year. The international sales increase was due to increased demand for V.A.C. systems and related disposables.
Rental Expenses: Rental, or "field," expenses of $259.8 million for the nine-month period increased $60.5 million, or 30.3%, from $199.3 million in the prior-year period. Rental expenses are variable and fluctuate with revenue. The field expense increase was directly associated with the growth in V.A.C. revenue, such as increased labor of $20.0 million, product licensing expenses of $12.8 million, incentive compensation of $7.4 million, rental equipment depreciation of $5.6 million, marketing expenses of $3.5 million, parts expense of $3.1 million and delivery expense of $2.1 million. Of the $60.5 million variance in rental expenses for the nine months ended September 30, 2003, approximately $12.2 million resulted from favorable foreign currency exchange rate fluctuations. Field expenses for the first nine months of 2003 represented 61.6% of total rental revenue compared to 61.3% in the first nine months of 2002.
Cost of Goods Sold: Cost of goods sold of $46.4 million in the first nine months of 2003 increased $9.8 million, or 26.7%, from $36.6 million in the prior year due to increased sales of V.A.C. disposables and higher excess and obsolescence inventory reserve provisions related to therapeutic surface products with low demand. Sales margins increased to 63.3% in the first nine months of 2003 as compared to 59.6% in the prior-year period due to the shift away from all-inclusive pricing arrangements discussed above and cost reductions resulting from favorable pricing in our global supply contract for V.A.C. disposables entered into in December 2002.
Gross Profit: Gross profit in the first nine months of 2003 increased approximately $61.9 million, or 34.4%, to $241.7 million from $179.8 million in the prior year due primarily to the year-to-year increase in revenue resulting from increased demand for V.A.C. systems and related disposables. Gross profit margin in the first nine months of 2003 was 44.1%, up slightly from 43.2% in the prior year due primarily to the increase in revenue discussed above.
Selling, General and Administrative Expenses: Selling, general and administrative expenses increased $31.4 million, or 30.5%, to $134.1 million in the first nine months of 2003 from $102.7 million in the prior-year period. This $31.4 million variance includes higher administrative costs of $12.1 million associated with hiring 276 personnel for our national call center and billing and collections departments, division labor and incentive compensation of $4.0 million, and product licensing expense of $2.3 million. Additionally, insurance costs of $3.3 million, professional fees of $2.6 million, engineering and manufacturing costs of $1.7 million and medical studies expenses of $1.4 million were all higher in the current period when compared to the prior year. As a percentage of total revenue, selling, general and administrative expenses decreased slightly to 24.5% in the first nine months of 2003 as compared to 24.7% in the first nine months of 2002.
Table of ContentsRecapitalization Expenses:
During the third quarter of 2003, we recognized $70.0 million in fees and expenses, excluding $16.3 million charged to interest expense, resulting from the transactions associated with the recapitalization. (See Note 2 of Notes to Condensed Consolidated Financial Statements.)Operating Earnings: Operating earnings for the first nine months of 2003 decreased $39.4 million, or 51.2%, to $37.7 million compared to $77.1 million in the prior-year period primarily due to expenses of $70.0 million recorded related to the recapitalization. Excluding recapitalization expenses, operating earnings would have increased $30.5 million over the prior year period, or 39.6%, to $107.6 million. This increase in operating earnings was directly attributable to the increase in revenue for the period, partially offset by higher operating costs and expenses. Operating margins for the first nine months of 2003, excluding recapitalization expenses, would have been 19.6%, up from 18.5% in the prior year period, due to the increase in revenue.
Non-GAAP Financial Information: We use earnings before interest, taxes, depreciation and amortization ("EBITDA") as a measure of leverage capacity and debt service ability. We consider EBITDA to be a key liquidity measure but it should not be considered as a measure of financial performance under GAAP or as an acceptable alternative to GAAP cash flows from operating activities, net income or operating income. Management uses this non-GAAP financial information to measure liquidity and we believe investors use the information for the same purpose. We have provided this supplemental non-GAAP information to demonstrate meaningful information regarding our liquidity on a consistent and comparable basis for the periods presented. Our definition of EBITDA is not necessarily comparable to similarly titled measures reported by other companies and is not the same as that term is used under our new senior credit agreement. The following table presents a reconciliation of EBITD A to cash flow from operating activities.
Nine months ended September 30, |
||||
2003 |
2002 |
|||
Net earnings |
$ 1,692 |
$ 29,132 |
||
Income tax expense |
1,015 |
19,422 |
||
Interest expense (1) |
41,562 |
30,877 |
||
Depreciation |
32,228 |
24,176 |
||
Amortization (2) |
479 |
1,146 |
||
______ |
_______ |
|||
EBITDA (3) |
76,976 |
104,753 |
||
Provision for uncollectible accounts receivable |
5,132 |
6,946 |
||
Amortization of deferred gain/leaseback on |
||||
headquarters facility |
(782) |
(171) |
||
Write-off of deferred loan fees |
5,233 |
- |
||
Non-cash accrual-recapitalization expenses |
8,907 |
- |
||
Non-cash amortization-stock award to directors |
92 |
- |
||
Amortization of loan issuance costs |
1,784 |
1,737 |
||
Income tax expense |
(1,015) |
(19,422) |
||
Interest expense (1) |
(41,562) |
(30,877) |
||
Change in assets and liabilities net of effects |
||||
from purchase of subsidiaries and |
||||
recapitalization expenses |
98,252 |
(10,121) |
||
______ |
_______ |
|||
Net cash provided by operating activities |
$153,017 |
$ 52,845 |
||
______ |
_______ |
(1) Amounts for 2003 include an aggregate of $16,302 in expense for the redemption premium and consent
fee paid in connection with the redemption of our 9 5/8% Senior Subordinated Notes due 2007 combined
with the write off of unamortized loan issuance costs associated with the previous senior credit facility.
(2) Net of amortization of loan issuance costs, which is included in interest expense.
(3) 2003 includes recapitalization expenses of $70.0 million.
Interest Expense:
Interest expense in the first nine months of 2003 was $41.6 million compared to $30.9 million in the prior year. This increase is primarily due to expenses related to the recapitalization completed in the third quarter of 2003. Excluding recapitalization expenses, interest expense would have decreased $5.6 million, or 18.2%, to $25.3 million. This decrease was due primarily to the partial paydown on our previously existing credit facility resulting from the $175 million antitrust settlement payment received in January 2003 and lower interest rates on our new senior credit facility and new subordinated notes. (See Notes 2, 5 and 9 of Notes to Condensed Consolidated Financial Statements.)
Net Earnings:
Net earnings of $1.7 million for the first nine months of 2003 decreased $27.4 million, or 94.2%, from the prior-year period primarily due to the expenses recorded related to the recapitalization. Excluding the recapitalization expenses, net earnings would have increased by $26.5 million, or 90.9%, to $55.6 million due to the increase in operating earnings discussed above. Effective tax rates for the first nine months of 2003 and 2002 were 37.5% and 40.0%, respectively.
Liquidity and Capital Resources
General
We require capital principally for capital expenditures, including the need for additional office space for our expanding workforce, systems infrastructure, debt service, interest payments and working capital. Our capital expenditures consist primarily of manufactured rental assets and computer hardware and software. Working capital is required principally to finance accounts receivable and inventory. Our working capital requirements vary from period to period depending on manufacturing volumes, the timing of shipments and the payment cycles of our customers and payers.
Sources of Capital
Based upon the current level of operations, we believe cash flows from operating activities and availability under the new revolving credit facility will be adequate to meet our anticipated cash requirements for interest payments, debt service, working capital and capital expenditures through 2004. During the first nine months of 2003, our primary source of capital was cash from operations. The following table summarizes the net cash provided and used by operating activities, investing activities and financing activities for the nine-month periods ended September 30, 2003 and 2002 (dollars in thousands):
Nine months ended September 30, |
||
2003 |
2002 |
|
Net cash provided by operating activities |
$ 153,017 (1) |
$ 52,845 |
Net cash used by investing activities |
(56,834) |
(25,358) |
Net cash provided (used) by financing activities |
(110,732) (2) (3) |
16,708 |
______ |
______ |
|
Total |
$ (14,549) |
$ 44,195 |
_____ |
_____ |
(1) Includes receipt of $107 million, net of taxes and related expenses paid, related to the Hillenbrand antitrust
settlement.
(2) Includes paydown of $107 million of indebtedness on the old senior credit facility utilizing funds received related to
the antitrust settlement.
(3) Includes cash recapitalization expenses of $20.7 million.
At September 30, 2003, cash and cash equivalents of $41.1 million were available for general corporate purposes. Availability under the revolving portion of our new credit facility was $88.7 million, net of $11.3 million in letters of credit, at September 30, 2003.
Table of ContentsWorking Capital
At September 30, 2003, we had current assets of $259.2 million, including $31.0 million in inventory, and current liabilities of $111.7 million resulting in a working capital surplus of $147.5 million, compared to a surplus of $243.9 million at December 31, 2002. The paydown of long-term obligations with funds from the payment received pursuant to the Hillenbrand antitrust settlement accounted for a majority of this change. Operating cash flows for the first nine months of 2003 were $153.0 million as compared to $52.8 million for the prior-year period. This increase in operating cash flows was due primarily to the Hillenbrand antitrust settlement, together with higher earnings excluding recapitalization expenses, and improved working capital management.
During the remainder of 2003, we expect rental and sales volumes for V.A.C. systems and related disposables to continue to increase, which could have the effect of increasing accounts receivable due to extended payment cycles for third party payers. We have adopted a number of policies and procedures to reduce these extended payment cycles, which we believe have been effective and will continue to improve our collection turnaround times. For example, our revenue for the first nine months of 2003 grew 31.8% over the prior-year period while our receivables have increased only 23.0% for the same period. If we were to have an increase in accounts receivable, we would expect to manage such an increase with available cash on hand and, if necessary, through increased borrowing under our new revolving credit facility. We expect that cash on hand, cash flow from operations and additional borrowings under our new revolving credit facility will be sufficient to meet our working capital needs.
Capital Expenditures
During the first nine months of 2003, we made net capital expenditures of $54.3 million compared to $38.8 million in the prior-year period. The period-to-period increase is primarily due to purchases of materials for V.A.C. systems and other high-demand rental products. As of September 30, 2003, we have commitments to purchase new product inventory of $16.6 million over the next twelve months. Other than commitments for new product inventory, we have no material long-term purchase commitments at the end of the period. We expect future demand for V.A.C. systems to increase, which will require increased capital expenditures over time.
Debt Service
As of September 30, 2003, scheduled principal payments remaining under the 2003 senior credit facility for the years 2003, 2004 and 2005 are $1.2 million, $4.8 million and $4.8 million, respectively.
Table of Contents
New Senior Credit Facility
The new senior credit facility consists of a $480.0 million seven-year term loan facility and a $100.0 million six-year revolving credit facility. The following table sets forth the amounts owing under the term loan and the revolving credit facility, the effective interest rates on such outstanding amounts, and amounts available for additional borrowing thereunder, as of September 30, 2003 (dollars in thousands):
Amount Available |
|||
Amounts |
For Additional |
||
Senior Credit Facility |
Effective Interest Rate |
Outstanding |
Borrowing |
Revolving credit facility |
- |
$ - |
$ 88,700 (2) |
Term loan facility |
4.86% (1) |
478,800 |
- |
_______ |
______ |
||
Total |
$ 478,800 |
$ 88,700 |
|
______ |
_____ |
(1) The effective interest rate includes the effect of interest rate hedging arrangements. Excluding the interest rate hedging
arrangements, our nominal interest rate as of September 30, 2003 was 3.89%.
(2) At September 30, 2003 and October 31, 2003, amounts available under the revolving portion of our credit facility
are reduced by $11.3 million of letters of credit issued on our behalf, none of which have been drawn upon by the
beneficiaries thereunder.
At September 30, 2003 and October 31, 2003, total borrowings under the senior credit facility were $478.8 million.
The senior credit facility contains affirmative and negative covenants customary for similar facilities and transactions including, but not limited to, quarterly and annual financial reporting requirements and limitations on other debt, other liens or guarantees, mergers or consolidations, asset sales, certain investments, distributions to shareholders or share repurchases, early retirement of subordinated debt, capital expenditures, changes in the nature of the business, changes in organizational documents and documents evidencing or related to indebtedness that are materially adverse to the interests of the lenders under the senior credit facility and changes in accounting policies or reporting practices.
- for any period of four consecutive quarters ending at the end of any fiscal quarter beginning with the fiscal
quarter ending December 31, 2003, the ratio of EBITDA, as defined, to consolidated cash interest expense
to be less than certain specified ratios ranging from 4.30 to 1.00, for the fiscal quarter ending December 31,
2003 to 5.50 to 1.00 for the fiscal quarter ending December 31, 2006 and each fiscal quarter following that quarter;
- as of the last day of any fiscal quarter beginning with the fiscal quarter ending December 31, 2003, our
leverage ratio of debt to EBITDA, as defined, to be greater than certain specified leverage ratios ranging
from 4.30 to 1.00 for the fiscal quarter ending December 31, 2003 to 2.50 to 1.00 for the fiscal quarter ending
December 31, 2006 and each fiscal quarter following that quarter; or
- for any period of four consecutive fiscal quarters ending at the end of any fiscal quarter beginning with
the fiscal quarter ending December 31, 2003, EBITDA, as defined, to be less than certain amounts
ranging from $156.4 million for the fiscal quarter ending December 31, 2003 to $240.0 million for the
fiscal quarter ending December 31, 2006 and each fiscal quarter following that quarter.
As of September 30, 2003 we were in compliance with all covenants under the senior credit agreement.
7 3/8% Senior Subordinated Notes due 2013
On August 11, 2003, we issued and sold an aggregate of $205.0 million principal amount of our 7 3/8% Senior Subordinated Notes due 2013. Interest on the notes accrues at the rate of 7 3/8% per annum and is payable semiannually in cash on each May 15 and November 15, commencing on November 15, 2003, to the persons who are registered holders at the close of business on May 1 and November 1 immediately preceding the applicable interest payment date. Interest on the notes accrues from and including the most recent date to which interest has been paid or, if no interest has been paid, from and including the date of issuance of the notes. Interest is computed on the basis of a 360-day year consisting of twelve 30-day months and, in the case of a partial month, the actual number of days elapsed. The notes are not entitled to the benefit of any mandatory sinking fund.
The notes are unsecured obligations of KCI, ranking subordinate in right of payment to all senior debt of KCI. The notes are guaranteed by each of our direct and indirect 100% owned subsidiaries, other than any entity that is a controlled foreign corporation within the definition of Section 957 of the Internal Revenue code or a holding company whose only assets are investments in a controlled foreign corporation. Each of these subsidiaries is a restricted subsidiary, as defined in the indenture governing the notes. (See Note 5 of the Notes to Condensed Consolidated Financial Statements.)
Each guarantor jointly and severally guarantees KCI's obligation under the notes. The guarantees are subordinated to guarantor senior debt on the same basis as the notes are subordinated to senior debt. The obligations of each guarantor under its guarantor senior debt will be limited as necessary to prevent the guarantor senior debt from constituting a fraudulent conveyance under applicable law.
The indenture governing the notes, limits our ability, among other things, to:
- incur additional debt;
- pay dividends, acquire shares of capital stock, make payments on subordinated debt or make investments;
- place limitations on distributions from our restricted subsidiaries;
- issue or sell capital stock of restricted subsidiaries;
- issue guarantees;
- sell or exchange assets;
- enter into transactions with affiliates;
- create liens; and
- effect mergers.
Interest Rate Protection
We have variable interest rate debt and other financial instruments, which are subject to interest rate risk and could have a negative impact on our business if not managed properly. We have a risk management policy, which is designed to reduce the potential negative earnings effect arising from the impact of fluctuating interest rates. We use interest rate swap agreements to minimize the impact of fluctuating interest rates. These contracts are initiated within the guidance of corporate risk management policies and are reviewed and approved by our top financial management. We do not use financial instruments for speculative or trading purposes.
Table of Contents
The following chart summarizes interest rate hedge transactions effective during the first nine months of 2003 (dollars in thousands):
Nominal |
Fixed |
||||||
Accounting Method |
Effective Dates |
Amount |
Interest Rate |
Status |
|||
Shortcut |
12/31/02 - 12/31/03 |
$ 80,000 |
1.745% |
Outstanding |
|||
Shortcut |
12/31/02 - 12/31/04 |
$ 100,000 |
2.375% |
Outstanding |
|||
Shortcut |
08/21/03 - 08/22/05 |
$ 60,000 |
2.150% |
Outstanding |
|||
Shortcut |
08/21/03 - 08/22/05 |
$ 20,000 |
2.130% |
Outstanding |
|||
Shortcut |
08/21/03 - 08/21/05 |
$ 20,000 |
2.135% |
Outstanding |
|||
Shortcut |
08/21/03 - 08/21/06 |
$ 50,000 |
2.755% |
Outstanding |
|||
Shortcut |
08/21/03 - 08/21/06 |
$ 50,000 |
2.778% |
Outstanding |
|||
Shortcut |
08/21/03 - 08/21/06 |
$ 50,000 |
2.788% |
Outstanding |
As of December 31, 2002, two $100 million interest rate swap agreements were in effect to take advantage of low interest rates. On January 31, 2003, we sold $20 million of our $100 million, 1.7450% interest rate swap effective March 31, 2003 which resulted in an expense of approximately $74,000 which was recorded in the first quarter of 2003. Our senior credit facility requires that we fix the base-borrowing rate applicable to at least 50% of the outstanding amount of our term loan under the senior credit facility for a period of two years from the date of issuance. In August 2003, we entered into six new interest rate swap agreements pursuant to which we fixed the rates on an additional $250 million of our variable rate debt. As a result of the eight swap agreements currently in effect as of September 30, 2003, 89.8% of our variable interest rate debt outstanding is fixed. (See Note 5 to Condensed Consolidatd Financial Statements.)
All of the interest rate swap agreements have quarterly interest payments, based on three month LIBOR, due on the last day of each March, June, September and December, commencing on September 30, 2003. The fair value of these swaps at inception was zero. Due to subsequent movements in interest rates, as of September 30, 2003, the fair values of these swap agreements were negative and were adjusted to reflect a liability of approximately $4.6 million. During the first nine months of 2003 and 2002, we recorded interest expense of approximately $1.6 million and $2.0 million, respectively as a result of interest rate protection agreements.
Long Term Commitments
We are committed to making cash payments in the future on long-term debt, capital leases, operating leases and purchase commitments. We have not guaranteed the debt of any other party. The following table summaries our contractual cash obligations as of September 30, 2003, for each of the periods indicated (dollars in thousands):
Operating |
||||||||||
Fiscal |
Long-Term Debt |
Capital Lease |
Lease |
Purchase |
||||||
Amortization |
Obligations |
Obligations |
Obligations |
Total |
||||||
2003 |
$ 1,350 |
$ 115 |
$ 16,805 |
$ 16,558 |
$34,828 |
|||||
2004 |
4,800 |
12 |
13,850 |
- |
18,662 |
|||||
2005 |
4,950 |
- |
11,473 |
- |
16,423 |
|||||
2006 |
4,950 |
- |
9,790 |
- |
14,740 |
|||||
2007 |
4,800 |
- |
7,633 |
- |
12,433 |
|||||
2008 |
4,800 |
- |
3,695 |
- |
8,495 |
|||||
Thereafter |
658,600 |
- |
12,655 |
- |
671,255 |
Critical Accounting Policies
The SEC defines critical accounting policies as those that are, in management's opinion, very important to the portrayal of our financial condition and results of operations and require our management's most difficult, subjective or complex judgments. In preparing our financial statements in accordance with generally accepted accounting
Table of Contentsprinciples in the United States, we must often make estimates and assumptions that effect the reported amounts of assets, liabilities, revenue, expenses and related disclosures at the date of the financial statements and during the reporting period. Some of those judgments can be subjective and complex. Consequently, actual results could differ from our estimates. The accounting policies that are most subject to important estimates or assumptions include those described below. (See Note 1 of Notes to Condensed Consolidated Financial Statements.)
Revenue Recognition
We recognize revenue in accordance with Staff Accounting Bulletin No. 101 when each of the following four criteria are met:
1. A contract or sales arrangement exists.
2. Products have been shipped and title has transferred or services have been rendered.
3. The price of the products or services is fixed or determinable.
4. Collectibility is reasonably assured.
We recognize rental revenue based on the number of days a product is in use by the patient/facility and the contracted rental rate. Reductions to rental revenue are recorded to provide for payment adjustments including capitation agreements, evaluation/free trial days, credit memos, rebates, pricing adjustments, utilization adjustments, cancellations and payer adjustments. In addition, we establish reserves against revenue to allow for uncollectible items relating to unbilled receivables over 60 days old and patient co-payments, based on historical collection experience.
Accounts Receivable-Allowance for Doubtful Accounts
We utilize a combination of factors in evaluating the collectibility of account receivables. For unbilled receivables, we establish reserves against revenue to allow for denied or uncollectible items beginning at 60 days after the end of service or usage. Items that remain unbilled for more than 90 days or beyond an established billing window are reversed out of revenue and receivables. For billed receivables, we generally establish reserves for bad debt based on the length of time that the receivables are past due. The reserve rates vary by payer group and are based upon our historical experience on a weighted average basis. The reserves range in value from 0% for current amounts to 50% for amounts over 180 days for most payer groups and 100% for certain higher risk payers. In addition, we have recorded specific reserves for bad debt when we become aware of a customer's inability to satisfy its debt obligations, such as in the event of a bankruptc y filing. If circumstances change, such as higher than expected claims denials, payment defaults or an unexpected material adverse change in a major customer's or payer's ability to meet its obligations, our estimates of the realizability of amounts due from trade receivables could be reduced by a material amount.
Goodwill and Other Intangible Assets
Goodwill represents the excess purchase price over the fair value of net assets acquired. Effective January 1, 2002, we applied the provisions of Statement of Financial Accounting Standards No. 142, ("SFAS 142"), Goodwill and Other Intangible Assets, in our accounting for goodwill. SFAS 142 requires that goodwill and other intangible assets that have indefinite lives not be amortized but instead be tested at least annually for impairment, or more frequently when events or changes in circumstances indicate that the asset might be impaired. For indefinite lived intangible assets, impairment is tested by comparing the carrying value of the asset to the fair value of the reporting unit to which they are assigned.
Goodwill was tested for impairment during the first and fourth quarters of 2002 and will be tested for impairment at least annually, in the fourth quarter, using a two-step process. The first step is a comparison of an estimation of the fair value of a reporting unit with the reporting unit's carrying value. We have determined that our reporting units are our two operating segments - USA and International. If the fair value of a reporting unit exceeds its carrying amount, the goodwill of the reporting unit is not considered impaired, and as a result, the second step of the impairment test is not required. If required, the second step compares the fair value of reporting unit goodwill
Table of Contentswith the carrying amount of that goodwill. If we determine that reporting unit goodwill is impaired, the fair value of reporting unit goodwill would be measured by comparing the discounted expected future cash flows of the reporting unit with the carrying value of reporting unit goodwill. Any excess in the carrying value of reporting unit goodwill to the estimated fair value would be recognized as an expense at the time of the measurement. We recorded no impairments to our reporting units as a result of the implementation of SFAS 142 during 2002.
The goodwill of a reporting unit will be tested annually or if an event occurs or circumstances change that would likely reduce the fair value of a reporting unit below its carrying amount. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition.
Inventory
Inventories are stated at the lower of cost (first-in, first-out) or market (net realizable value). Costs include material, labor and manufacturing overhead costs. Inventory expected to be converted into equipment for short-term rental is reclassified to property, plant and equipment. We review our inventory balances monthly for excess sale products or obsolete inventory levels. Except where firm orders are on-hand, inventory quantities of sale products in excess of the last twelve months demand are considered excess and are reserved at 50% of cost. For rental products, we review both product usage and product life cycle to classify inventory as active, discontinued or obsolete. Obsolescence reserve balances are established on an increasing basis from 0% for active, high-demand products to 100% for obsolete products. The reserve is reviewed, and if necessary, adjustments made on a monthly basis. We rely on historical information to support our reserve and utilize management's business judgment for "high risk" items, such as products that have a fixed shelf life. Once the inventory is written down, we do not adjust the reserve balance until the inventory is sold.
Long-Lived Assets
Property, plant and equipment are stated at cost. Betterments, which extend the useful life of the equipment, are capitalized. Depreciation on property, plant and equipment is calculated on the straight-line method over the estimated useful lives (30 to 40 years for buildings and between three and five years for most of our other property and equipment) of the assets. We have not had an event that would indicate impairment of our tangible long-lived assets. If an event were to occur, we would review property, plant and equipment for impairment using an undiscounted cash flow analysis and if an impairment had occurred on an undiscounted basis, we would compute the fair market value of the applicable assets on a discounted cash flow basis and adjust the carrying value accordingly.
Income Taxes
We operate in multiple tax jurisdictions both inside and outside the United State, with different tax rates, accordingly we must determine the appropriate allocation of income in accordance with local law for each of these jurisdictions. In the normal course of our business, we will undergo scheduled reviews by taxing authorities regarding the amount of taxes due. These reviews include questions regarding the timing and amount of deductions and the allocation of income among various tax jurisdictions. Tax reviews often require an extended period of time to resolve and may result in income tax adjustments if changes to the allocation are required between jurisdictions with different tax rates. We believe our income tax accruals are adequate to cover exposures related to such potential changes in income allocations between jurisdictions. To the extent additional information becomes available, such accruals are adjusted to reflect probable outcomes .
Legal Proceedings and Other Loss Contingencies
We are subject to various legal proceedings, many involving routine litigation incidental to our business. The outcome of any legal proceeding is not within our complete control, is often difficult to predict and is resolved over very long periods of time. Estimating probable losses associated with any legal proceedings or other loss contingencies is very complex and requires the analysis of many factors including assumptions about potential
Table of Contentsactions by third parties. Loss contingencies are recorded as liabilities in the consolidated financial statements when it is both (1) probable or known that a liability has been incurred and (2) the amount of the loss is reasonably estimable, in accordance with Financial Accounting Standards Statement No. 5, "Accounting for Contingencies." If the reasonable estimate of the loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability. If a loss contingency is not probable or not reasonably estimable, a liability is not recorded in the consolidated financial statements.
New Accounting Pronouncements
In January 2003, the Financial Accounting Standards Board ("FASB") issued Interpretation No. 46, or ("FIN 46"), "Consolidation of Variable Interest Entities." This interpretation is now effective for fiscal years or interim periods ending after December 15, 2003. FIN 46 addresses accounting for, and disclosure of, variable interest entities. FIN 46 requires the disclosure of the nature, purpose and exposure of any loss related to our involvement with variable interest entities. We adopted the provisions of FIN 46 for post-January 31, 2003 variable interest entities during the first quarter of 2003 and it did not have a significant effect on our financial position or results of operations. We continue to evaluate the potential effects of the consolidation provisions of FIN 46 that will be adopted during the fourth quarter of 2003.
Specifically, we are evaluating the consolidation provisions of FIN 46 on our beneficial ownership of two Grantor Trusts, which we acquired in December 1996 and December 1994. The assets held by each Trust consist of a McDonnell Douglas DC-10 aircraft and three engines. In connection with the acquisitions, KCI paid cash of $7.2 million and $7.6 million, respectively. At the date of the acquisition, the Trusts held debt of $48.4 million and $51.8 million, respectively, which is non-recourse to KCI. The aircraft are leased to the Federal Express Corporation through June 2012 and January 2012, respectively. Federal Express pays monthly rent to a third party who, in turn, pays the entire amount to the holders of the non-recourse indebtedness, which is secured by the aircraft. The holder's recourse in event of a default is limited to the Trusts assets.
In April 2003, the FASB issued Statement of Financial Accounting Standards No. 149, or ("SFAS 149"), "Amendment of Statement 133 on Derivative Instruments and Hedging Activities." This statement amends SFAS 133 to provide clarification on the financial accounting and reporting of derivative instruments and hedging activities and requires contracts with similar characteristics to be accounted for on a comparable basis. We do not expect the adoption of SFAS 149, which will be effective for contracts entered into or modified after September 30, 2003, to have a material effect on our financial condition or results of operations.
On May 15, 2003, the FASB issued SFAS 150, "Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity." The statement established standards for classifying and measuring as liabilities certain financial instruments that embody obligations of the issuer and have characteristics of both liabilities and equity. SFAS 150 must be applied immediately to instruments entered into or modified after May 31, 2003. We have applied the terms of SFAS 150 to the convertible preferred stock issued as a part of the recapitalization and determined that it should be classified as equity and will be reported in the mezzanine section of our balance sheet. All dividends paid or accrued on the preferred stock will be reported as dividends in the Condensed Consolidated Statements of Operations.
Table of Contents
RISK FACTORS
Our business faces significant risks. You should carefully consider the risks described below together with all other information in and incorporated by reference into this report.
Risks Related to Our Capital Structure
Our substantial indebtedness could adversely affect our financial condition and prevent us from fulfilling our obligations under the 7 3/8% Senior Subordinated Notes due 2013.
We have a significant amount of debt. As of September 30, 2003, we had $689.0 million of outstanding indebtedness (long-term debt, capital lease obligations and our liability associated with interest rate swaps) and a shareholders' deficit of $580.1 million. This level of indebtedness could have important consequences, including the following:
- it may be difficult for us to satisfy our obligations under our new senior credit facility and the notes;
- we may have to use a significant amount of our cash flow for scheduled debt service rather than for operations;
- we may be less able to obtain other debt financing in the future;
- we could be less able to take advantage of significant business opportunities, including acquisitions or
divestitures;
- our vulnerability to general adverse economic and industry conditions could be increased; and
- we could be at a competitive disadvantage to competitors with less debt.
Servicing our debt requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our substantial debt.
We expect to obtain the money to make payments on our debt and to fund working capital, capital expenditures and other general corporate requirements in part from our operations and the operations of our subsidiaries. Our ability to generate cash in the future is, to some extent, subject to risks and uncertainties that are beyond our control. If we are unable to meet our debt obligations, we may need to refinance all or a portion of our indebtedness, sell assets or raise funds in the capital markets. Our ability to refinance will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations.
Restrictive covenants in the new senior credit agreement and the indenture may restrict our ability to pursue our business strategies.
The indenture governing the 7 3/8% Senior Subordinated Notes due 2013 and the new senior credit facility limit our ability, among other things, to:
- incur additional indebtedness or contingent obligations;
- pay dividends or make distributions to our shareholders;
- repurchase or redeem our stock;
- make investments;
- grant liens;
- make capital expenditures;
- enter into transactions with our shareholders and affiliates;
- sell assets; and
- acquire the assets of, or merge or consolidate with, other companies.
The senior credit facility contains financial covenants requiring us to meet certain leverage and interest coverage ratios and maintain minimum levels of EBITDA (as defined in the senior credit agreement). Under the senior credit agreement, EBITDA excludes charges associated with the recapitalization. It will be an event of default if we permit any of the following:
- for any period of four consecutive quarters ending at the end of any fiscal quarter beginning with the fiscal
quarter ending December 31, 2003, the ratio of EBITDA to consolidated cash interest expense to be less than
certain specified ratios ranging from 4.30 to 1.00 for the fiscal quarter ending December 31, 2003 to 5.50 to
1.00 for the fiscal quarter ending December 31, 2006 and each fiscal quarter following that quarter;
- as of the last day of any fiscal quarter beginning with the fiscal quarter ending December 31, 2003, the leverage
ratio of debt to EBITDA, as defined, to be greater than certain specified leverage ratios ranging from
4.30 to 1.00 for the fiscal quarter ending December 31, 2003 to 2.50 to 1.00 for the fiscal quarter ending
December 31, 2006 and each fiscal quarter following that quarter; or
- for any period of four consecutive fiscal quarters ending at the end of any fiscal quarter beginning with the
fiscal quarter ending December 31, 2003, EBITDA to be less than certain amounts ranging from $156.4 million
for the fiscal quarter ending December 31, 2003 to $240.0 million for the fiscal quarter ending December 31,
2006 and each fiscal quarter following that quarter.
We may not be able to maintain these ratios. Covenants in the new senior credit facility may also impair our ability to finance future operations or capital needs, or to enter into acquisitions or joint ventures or engage in other favorable business activities.
If we default under the new senior credit facility, we could be prohibited from making any payments on the 7 3/8% Senior Subordinated Notes due 2013. In addition, the lenders under the new senior credit facility could require immediate repayment of the entire principal. If those lenders require immediate repayment, we may not be able to repay them and also repay the notes in full. If we are unable to generate sufficient cash flow or otherwise obtain funds necessary to make required payments under the new senior credit facility, or if we are unable to maintain the financial ratios under the new senior credit facility, we will be in default under the credit agreement, which could, in turn, cause a default under the notes, the related indenture and any other debt obligations that we may incur from time to time.
Despite our substantial debt, we may incur additional indebtedness, including senior debt, which would increase the risks described above.
We may be able to incur additional debt, including senior debt, in the future. The indenture for the 7 3/8% Senior Subordinated Notes due 2013 and our new senior credit facility do not completely prohibit us from incurring additional debt. As of September 30, 2003, we had $88.7 million (net of outstanding letters of credit of $11.3 million) of total availability for potential borrowing under our new revolving credit facility, subject to our compliance with the financial and other covenants included in our new revolving credit facility. Any future borrowings we make under our new revolving credit facility will be senior to the new notes and the subsidiary guarantees. In addition, the indenture allows us to incur debt that may be senior to the notes. If new debt is added to KCI's and its subsidiaries' current debt levels, the risks related to KCI and the subsidiary guarantors' abilities to service that debt and its impact on our respective operations that we and they now face could increase.
Risks Related to Our Business
We face significant competition which may cause us to lose business.
The competition for our V.A.C. systems in wound healing and tissue repair consists in large part of wound-healing modalities which do not operate in a manner similar to V.A.C. systems, including traditional wound care
Table of Contentsdressings, advanced wound care dressings, skin substitutes, products containing growth factors and medical devices used for wound care. Recently, BlueSky Medical Corporation introduced a medical device which has been marketed to compete with the V.A.C. system. We have filed suit against BlueSky and related parties seeking to enjoin their continued marketing and sales of the device, which we believe infringes our patent rights (see "Part II-Other Information. Item 1. Legal Proceedings"). If any product similar to the V.A.C. system is introduced into the market by a legitimate competitor and protections afforded us under intellectual property laws do not operate to prevent the sale of the product, we could lose market share or experience downward pricing pressure from decreased demand.
Our primary competitor in the therapeutic surface business is Hill-Rom Company, whose financial and other resources substantially exceed those available to us. In Europe, we also face competition from Huntleigh Healthcare and Pegasus Limited.
Competitive conditions could intensify in our markets. Competitors may:
- develop or commercialize new technologies which are more effective than our products;
- introduce new competing products with greater safety or efficacy or at lower prices;
- secure exclusive arrangements with health care providers and GPOs;
- devote greater resources to marketing and promotional campaigns;
- secure regulatory clearances or approvals that surpass those of our products; or
- obtain services, products and materials from suppliers on more favorable terms.
We may incur substantial costs in protecting our intellectual property, and if we are unable to effectively protect it, our competitive position would be harmed.
We place considerable importance on obtaining and maintaining patent protection for our products. We have numerous patents on our existing products and processes and we file applications as appropriate for patents covering new technologies as they are developed. However, the patents we own, or in which we have rights, may not be sufficiently broad to protect our technology position against competitors. Issued patents owned by, or licensed to, us may be challenged, invalidated or circumvented, or the rights granted under the patent may not provide us with competitive advantages. We would incur substantial costs and diversion of management resources if existing disputes are not resolved amicably, or if we have to assert our patent rights against others. Any unfavorable outcome in intellectual property disputes or litigation could cause us to lose our intellectual property rights in technology that is material to our products. In addition, we may not be able to detect infringement by third parties, and could lose our competitive position if we fail to do so quickly.
Further, our efforts to protect our intellectual property rights may be less effective in some countries where intellectual property rights are not as well protected as in the United States. Many U.S. companies have encountered substantial problems in protecting their proprietary rights against infringement in foreign countries. If we fail to adequately protect our intellectual property rights in these countries, it could be easier for our competitors to sell competing products.
We also rely on a combination of copyright, trade secret and other laws, and contractual restrictions on disclosure, copying and transferring title, including confidentiality agreements with vendors, strategic partners, co-developers, employees, consultants and other third parties, to protect our proprietary rights. Such protections may not prove adequate and such contractual agreements may be breached. We may not have adequate remedies for any such breaches, and our trade secrets may otherwise become known to or independently developed by others. We have trademarks, both registered and unregistered, that are maintained and enforced to provide customer recognition for our products in the marketplace. Our trademarks may be used by unauthorized third parties, and we may not be able to stop such unauthorized use if it occurs. We also have agreements with third parties that provide for licensing of patented or proprietary technologies. These agreements include royalty-bearing licenses. If we were to lose the rights to license these technologies, or our costs to license these technologies were to materially increase, our business would suffer.
Table of Contents
We may be sued by third parties for alleged infringement of their proprietary rights, which could harm our competitive position.
The markets in which we compete are characterized by a substantial amount of litigation over patent and other intellectual property rights. Our competitors, like companies in other high technology businesses, continually review other companies' products for possible conflicts with their own intellectual property rights. Determining whether a product infringes a third party's intellectual property rights involves complex legal and factual issues, and the outcome of this type of litigation is often uncertain. Third parties may claim that we are infringing their intellectual property rights, and we may be found to infringe those intellectual property rights.
If we are unable to develop new generations of products and enhancements to existing products, we may be unable to attract or retain customers.
Our success is dependent upon the successful development, introduction and commercialization of new generations of products and enhancements to existing products. Our products are technologically complex and must keep pace with rapid and significant technological change, must comply with rapidly evolving industry standards and must compete effectively with new product introductions of our competitors. Accordingly, many of our products require significant planning, design, development and testing at the technological, product and manufacturing process levels. These activities require significant capital commitments and investments on our part, which we may be unable to recover.
Because we depend on revenue from sales and rental of V.A.C. products, our financial condition could suffer if V.A.C. sales and rentals do not grow.
For the nine-month period ended September 30, 2003, we derived 61.9% of our revenue from V.A.C. sales and rentals. We expect that sales and rentals of V.A.C. products will continue to be the predominant source of our revenue for the foreseeable future. If revenue from our V.A.C. sales and rentals does not grow as we anticipate, our results of operations and financial condition could suffer.
Health care reform could decrease demand for our products.
There are widespread legislative efforts to control health care costs in the United States and abroad, which we expect will continue in the future. In the past, these have included freezes in annual payment updates, cuts in payment reimbursement amounts and efforts to competitively bid durable medical equipment. Similar legislative efforts in the future could negatively impact demand for our products.
Changes to third-party reimbursement policies could reduce the reimbursement we receive for our products.
Our products are rented and sold to hospitals and skilled nursing facilities that receive reimbursement for the products and services they provide from various public and private third party payers, including Medicare, Medicaid and private insurance programs. We also act as a DME supplier and, as such, we furnish our products directly to customers and bill third-party payers such as Medicare, Medicaid and private insurance. As a result, the demand for our products in any specific care setting is dependent, in part, on the reimbursement policies (including coverage and payment policies) of the various payers in that setting. Some state and private payers make adjustments to their reimbursement policies to reflect federal changes as well as to make their own changes. If coverage and payment policies for our products are revised or otherwise withdrawn under existing Medicare or Medicaid policies, demand for our products could decrease. In addit ion, in the event any public or private third-party payers challenge our billing, documentation or other practices as inconsistent with their reimbursement policies, we could experience significant delays, reductions or denials in obtaining reimbursements. In light of increased controls on health care spending, especially on Medicare and Medicaid spending, the outcome of future coverage or payment decisions for any of our products by governmental or private payers remain uncertain.
The Medicare Part B coverage policy covering V.A.C. systems is complex and requires extensive documentation. In addition, the reimbursement process for the non-governmental payer segment requires extensive
Table of Contentscontract development and administration with several hundred payers, with widely varying requirements for documentation and administrative procedures, which can result in extended payment cycles. This has made billing home care payers more complex and time consuming than billing other payers. In 2003, the Centers for Medicare and Medicaid Services issued new regulations on inherent reasonableness of such charges and while these regulations do not impact us currently, future coverage or payment decisions could impact our V.A.C. systems or any of our other products. If providers, suppliers and other users of our products and services are unable to obtain sufficient reimbursement for the provision of our products, demand for our products will decrease.
If we are not able to timely collect reimbursement payments, our financial condition may suffer.
As of September 30, 2003, we had $170.6 million of receivables outstanding, net of reserves of $34.1 million for doubtful accounts, and for the twelve-month period ended September 30, 2003, our receivables were outstanding for an average of 79 days. If our collection policies and procedures are not effective, we may not be able to timely collect our reimbursement payments.
We may be subject to claims audits which would harm our business and financial results.
As a health care supplier, we are subject to extensive government regulation, including laws regulating reimbursement under various government programs. The billing, documentation and other practices of health care suppliers are subject to government scrutiny, including claims audits. To ensure compliance with Medicare regulations, contractors, such as the Durable Medical Equipment Regional Carriers, or DMERCs which serve as the government's agents for the processing of claims for products sold for home use, periodically conduct audits and request medical records and other documents to support claims submitted by us for payment of services rendered to our customers. Because we are a DME supplier, those audits involving home use involve audits of patient claims records. Such audits can result in delays in obtaining reimbursement and denials of claims for payment submitted by us.
For example, we recently received the results of a routine review conducted by the DMERC for Region A. The review included a sample of 30 claims billed to Medicare for negative pressure wound therapy pumps and supplies between October 1, 2000, and December 31, 2001, from each of our top three billing locations in Region A. In their first review, the DMERC identified certain medical record documentation deficiencies. This resulted in an alleged overpayment of approximately $620,000. In rebuttal of those decisions, we submitted supplemental documentation to the Region A DMERC. After review of the additional information, the DMERC reduced the total amount of total overpayment to approximately $110,000. We are also reviewing the rebuttal decisions to determine which, if any, of the denied claims should be appealed for review by an administrative law judge.
Also, in December 2002, we submitted a written request to the medical directors of the four DMERCs in which we requested clarification of a number of issues with respect to the DMERCs' "Negative Pressure Wound Therapy Policy." That policy establishes Medicare Part B reimbursement criteria for our V.A.C. products. In June 2003, we received a response from the medical directors and, in some instances, their interpretation of the policy differed from our interpretation. In September 2003, we learned that one of the DMERCs published in its regional newsletter an interpretation of the policy consistent with its June response. Also in September 2003, we began to experience an increase in Medicare Part B denials for V.A.C. placements. Although difficult to quantify, we estimate that the reimbursement coverage issues under the DMERCs' policy relate to less than 10% of our Medicare V.A.C. revenue, or approximately 1% of our overall revenue. We have provided the medical directors with a response to their interpretation and have spoken to one of the DMERC medical directors to support our interpretation of the policy. We intend to continue working with the medical directors in an effort to clarify the policy while at the same time maintaining coverage for all Medicare Part B beneficiaries for whom V.A.C. treatment is medically necessary. In the event that the medical directors do not agree to revise their interpretations on these issues, the rate of V.A.C. revenue growth could be impacted.
In addition, the government could demand significant refunds or recoupments of amounts paid by the government for claims which are determined by the government to be inadequately supported by the required documentation.
Table of ContentsBecause we depend upon a limited group of suppliers and, in some cases, sole-source suppliers, we may incur significant product development costs and experience material delivery delays if we lose any supplier.
We obtain some of the components included in our products from a limited group of suppliers, and, in one case, a sole-source supplier. We have entered into a sole-source agreement with Avail Medical Products, Inc., or Avail, for V.A.C. disposables, effective October 2002 for our U.S.-related orders and mid-2003 for our international-related orders. This supply agreement has a three-year term with an automatic extension for an additional twelve months if neither party gives notice of termination. If we lose any supplier (including any sole-source supplier), we would be required to obtain one or more replacement suppliers and may be required to conduct a significant level of product development to incorporate new parts into our products. The need to change suppliers or to alternate between suppliers might cause material delays in delivery or significantly increase costs.
Our rates may decline or be less predictable due to the economic, political and other risks associated with our high percentage of international sales.
For the nine-month period ending September 30, 2003, approximately 24% of our revenue, and approximately 15% of our operating earnings (excluding the Hillenbrand settlement and recapitalization expenses), were derived from our international segment. We intend to continue to expand our presence in international markets. Accordingly, our future results could be harmed by a variety of factors, including:
- the difficulties in enforcing agreements and collecting receivables under many foreign countries' legal systems;
- the longer payment cycles associated with many foreign customers;
- the possibility that foreign countries may impose additional withholding taxes or otherwise tax our foreign
income, impose tariffs or adopt other restrictions on foreign trade;
- fluctuations in exchange rates, which may affect products demand and adversely affect the profitability, in U.S.
dollars, of products and services provided by us in foreign markets where payment for our products and
services is made in the local currency;
- our ability to obtain U.S. export licenses and other required export or import licenses or approvals;
- changes in the political, regulatory, safety or economic conditions in a country or region; and
- the protection of intellectual property in foreign countries may be more difficult to enforce.
If we are unable to manage rapid changes, our business may be harmed.
We are currently experiencing significant growth in revenue, employees and number of product offerings. This growth has placed a significant strain on our management and our financial, operational, marketing and sales systems. Any failure by us to properly manage our growth could impair our ability to attract and service customers and could cause us to incur higher operating costs and experience delays in the execution of our business plan. We have also experienced reductions in revenue in the past that required us to rapidly reduce costs.
We are subject to numerous laws and regulations governing the health care industry, and non-compliance with such laws, as well as changes in such laws or future interpretations of such laws, could limit out ability to distribute our products and could cause us to incur significant compliance costs.
Substantially all of our products are subject to regulation by the U.S. Food and Drug Administration, or FDA, and its foreign counterparts. Complying with FDA requirements and other applicable regulations imposes significant costs and expenses on our operations. If we fail to comply with applicable regulations, we could be subject to enforcement sanctions, our promotional practices may be restricted, and our marketed products could be subject to recall or otherwise impacted. In addition, new regulations, such as the U.S. Health Insurance Portability and Accountability Act of 1996, or HIPAA, that regulate the way we do business will result in increased compliance costs.
We are also subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, privacy and security of individually identifiable health information, standardization of electronic data transactions and code sets, environmental protection, fire hazard control and disposal of hazardous or
Table of Contentspotentially hazardous substances. Changes in existing requirements or adoption of new requirements could cause us to incur significant compliance costs.
We are also subject to various federal and state laws pertaining to health care fraud and abuse, including prohibitions on the submission of false claims and the payment or acceptance of kickbacks or other remuneration in return for the purchase or lease of our products. The United States Department of Justice and the Office of the Inspector General of the United States Department of Health and Human Services has launched an enforcement initiative which specifically targets the long term care, home health and DME industries. Sanctions for violating these laws include criminal penalties and civil sanctions, including fines and penalties, and possible exclusion from the Medicare, Medicaid and other federal health care programs. Although we believe our business arrangements comply with federal and state fraud and abuse laws, our practices may be challenged under these laws in the future.
Product liability claims could expose us to significant costs associated with adverse judgments or could reduce the demand for our products.
The manufacturing and marketing of medical products necessarily entails an inherent risk of product liability claims. If a product liability claim is successfully asserted against us and we become liable for amounts in excesses of our insurance coverage, we could be responsible for potentially large litigation damage awards and costs and expenses in litigating such a claim.
Our voting stock is controlled by three principal shareholders, whose interests may conflict with those of the holders of the new notes.
As of November 10, 2003, Dr. Leininger, who is our founder and a member of our board of directors, 30.7% of our outstanding shares of voting stock, which consists of common stock and preferred stock entitled to the same voting rights as our common stock. In addition, Fremont Partners, L.P. owns 36.4% of our outstanding shares of voting stock and Blum Capital Partners, L.P. owns 24.1% of our outstanding shares of voting stock. As a result of this ownership, Dr. Leininger, Fremont Partners, L.P. and Blum Capital Partners, L.P. are able to direct our affairs and to approve any matter requiring the approval of our shareholders. Such matters include the election of directors, the adoption of amendments to our articles of incorporation and approval of mergers or sales of substantially all our assets. The interests of our principal shareholders may conflict with the interests of the holders of the new notes.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are exposed to various market risks, including fluctuations in interest rates and variability in currency exchange rates. We have established policies, procedures and internal processes governing our management of market risk and the use of financial instruments to manage our exposure to such risk.
Interest Rate Risk
We have variable interest rate debt and other financial instruments, which are subject to interest rate risk and could have a negative impact on our business if not managed properly. We have a risk management policy, which is designed to reduce the potential negative earnings effect arising from the impact of fluctuating interest rates. We use interest rate swap agreements to minimize the impact of fluctuating interest rates. These contracts are initiated within the guidance of corporate risk management policies and are reviewed and approved by our top financial management. We do not use financial instruments for speculative or trading purposes.
Our 2003 senior credit facility requires that we fix the base-borrowing rate applicable to at least 50% of the outstanding amount of our term loan under the senior credit facility for a period of two years from the date of issuance. As of September 30, 2003, we have eight interest rate swap agreements pursuant to which we have fixed the rates on $430.0 million of our variable rate debt as follows:
1.745% per annum on $80 million of our variable rate debt through December 31, 2003;
2.375% per annum on $100 million of our variable rate debt through December 31, 2004;
2.150% per annum on $60 million of our variable rate debt through August 22, 2005;
2.130% per annum of $20 million of our variable rate debt through August 22, 2005;
2.135% per annum on $20 million of our variable rate debt through August 21, 2005;
2.755% per annum on $50 million of our variable rate debt through August 21, 2006;
2.778% per annum on $50 million of our variable rate debt through August 21, 2006;
2.788% per annum on $50 million of our variable rate debt through August 21, 2006.
As a result of the eight swap agreements currently in effect as of September 30, 2003, 89.8% of our variable interest rate debt outstanding is fixed.
All interest rate swap agreements have quarterly interest payments, based on three month LIBOR, due on the last day of each March, June, September and December, commencing on September 30, 2003. The fair value of these swaps at inception was zero. Due to subsequent movements in interest rates, as of September 30, 2003, the fair values of these swap agreements were negative and were adjusted to reflect a liability of approximately $4.6 million.
The table below provides information about our long-term debt and interest rate swaps, both of which are sensitive to changes in interest rates. For long-term debt, the table presents principal cash flows and related weighted average interest rates by expected maturity dates. For interest rate swaps, the table presents notional amounts and weighted average interest rated by expected (contractual) maturity dates. Notional amounts are used to calculate the contractual payments to be exchanged under the contract. Weighted average variable rates are based on implied forward rates in the field curve at the reporting date (dollars in thousands):
September 30, 2003 |
|||||||||||||
Expected maturity date |
|||||||||||||
Fair |
|||||||||||||
2003 |
2004 |
2005 |
2006 |
Thereafter |
Total |
Value |
|||||||
Long-term debt |
|||||||||||||
Fixed rate |
$ 150 |
- |
$ 150 |
$ 150 |
$205,000 |
$205,450 |
$211,100 |
||||||
Average interest rate |
7.000% |
- |
7.000% |
7.000% |
7.375% |
7.374% |
|||||||
Variable rate |
$ 1,200 |
$ 4,800 |
$ 4,800 |
$ 4,800 |
$463,200 |
$478,800 |
$478,800 |
||||||
Average interest rate |
3.890% |
3.890% |
3.890% |
3.890% |
- |
3.890% |
|||||||
Interest rate swaps (1) |
|||||||||||||
Variable to fixed |
$80,000 |
$100,000 |
$100,000 |
$150,000 |
- |
$430,000 |
$ (4,601) |
||||||
Average pay rate |
1.745% |
2.375% |
2.143% |
2.780% |
- |
2.343% |
|||||||
Average receive rate |
1.140% |
1.140% |
1.140% |
1.140% |
- |
1.140% |
(1) Interest rate swaps are included in the variable rate debt under long-term debt.
Foreign Currency and Market Risk
We have direct operations in Western Europe, Canada, Australia and South Africa and distributor relationships in many other parts of the world. Our foreign operations are measured in their applicable local currencies. As a result, our financial results could be affected by factors such as changes in foreign currency exchange rates or weak economic conditions in the foreign markets in which we have operations. Exposure to these fluctuations is managed primarily through the use of natural hedges, whereby funding obligations and assets are both managed in the applicable local currency.
We maintain no other derivative instruments to mitigate our exposure to translation and/or transaction risk. International operations reported operating profit of $16.4 million for the nine months ended September 30, 2003. It is estimated that a 10% fluctuation in the value of the dollar relative to these foreign currencies at September 30, 2003 would change our net income for the nine months ended September 30, 2003 by approximately $1.2 million. Our analysis does not consider the implications that such fluctuations could have on the overall economic activity
Table of Contentsthat could exist in such an environment in the U.S. or the foreign countries or on the results of operations of these foreign entities.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
As of the end of the fiscal quarter covered by this report, an evaluation was performed under the supervision and with the participation of management, including the Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended). Based on that evaluation, our management, including the Chief Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures were effective as of the evaluation date. During the fiscal quarter covered by this report, there have been no material changes in our disclosure controls and procedures or in other factors, which could significantly affect such controls and procedures.
Changes in Internal Control
During the fiscal quarter covered by this report, there have been no significant changes in KCI's internal control (as such term is defined in rule 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended) or in other factors which could significantly affect internal control.
PART II - OTHER INFORMATION
In August 2003, KCI and Wake Forest University filed a lawsuit against BlueSky Medical Corporation and related parties alleging infringement of multiple claims under two V.A.C. patents arising from the manufacturing and marketing of a medical device by BlueSky. KCI and Wake Forest have asserted additional related claims which, together with the infringement claims, we believe are meritorious. Otherwise, there have been no material changes from the information provided in KCI's Annual Report on Form 10-K for the year ended December 31, 2002 in regard to legal proceedings.
ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS
On August 11, 2003, KCI issued $205 million in principal amount of 7 3/8% Senior Subordinated Notes due 2013 in an unregistered offering to qualified institutional buyers under Securities Act Rule 144A and outside the United States in compliance with Regulation S. For a description of the notes, see Note 5 of the Notes to the Condensed Consolidated Financial Statements. Also on August 11, 2003, KCI issued $263.8 million of Series A Convertible Participating Preferred Stock to accredited investors in compliance with Regulation D. The preferred stock ranks senior to common stock with respect to liquidation and dividends and is mandatorily redeemable with the passage of time. Except as otherwise provided by law, holders of preferred stock are entitled to vote together with our common shareholders and are entitled to vote on an as-converted basis. For a more complete description of the preferred stock, see Note 6 of Notes to the Condensed Consol idated Financial Statements.
Table of Contents SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERSDuring the third quarter of 2003, a special meeting of shareholders was held on August 1, 2003 to consider and act on the following items:
- The adoption of an amendment to the Articles of Incorporation of KCI authorizing a class of preferred stock
and giving the board of directors authority to fix and determine the designations, preferences, limitations and
relative rights of the preferred stock and any series thereof; and
- The approval and adoption of the 2003 Non-employee Director Stock Plan.
The shareholders adopted both of these items with 70,927,426 votes cast in favor of their adoption and no votes cast against or abstaining.
Table of ContentsITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits
A list of all exhibits filed or included as part of this quarterly report on form 10-Q is as follows:
Exhibits |
Description |
3.1 |
Restated Articles of Incorporation (filed as Exhibit 3.1 to our Registration Statement on Form S-4 filed on September 29, 2003, as thereafter amended). |
3.2 |
Articles of Amendment to the Amended and Restated Articles of Incorporation of KCI (filed as Exhibit 3.2 to our Registration Statement on form S-4 filed on September 29, 2003, as thereafter amended). |
3.3 |
Amended and Restated By-Laws of KCI (filed as Exhibit 3.3 to our Registration Statement on Form S-4 filed on September 29, 2003, as thereafter amended). |
4.1 |
Indenture, dated as of August 11, 2003, among KCI, as Issuer, the Guarantors, and U.S. Bank National Association, as Trustee (filed as Exhibit 4.1 to our Registration Statement of Form S-4 filed on September 29, 2003, as thereafter amended). |
4.2 |
Form of Series B 7 3/8% Senior Subordinated Notes due 2013 (included in Exhibit 4.1) (filed as Exhibit 4.2 to our Registration Statement on Form S-4 filed on September 29, 2003, as thereafter amended). |
10.1 |
Registration Rights Agreement, dated as of August 11, 2003, among KCI, as Issuer, the Guarantors, and Morgan Stanley & Co. Incorporated, Credit Suisse First Boston LLC, Goldman, Sachs & Co., J.P. Morgan Securities Inc., Scotia Capital (USA) Inc., and Wells Fargo Securities, LLC, as Placement Agents (filed as Exhibit 10.1 to our Registration Statement on Form S-4 filed on September 29, 2003, as thereafter amended). |
10.2 |
Credit Agreement, dated as of August 11, 2003 (filed as Exhibit 10.2 to our Registration Statement on Form S-4 filed on September 29, 2003, as thereafter amended). |
10.3 |
Guarantee and Collateral Agreement, dated as of August 11, 2003 (filed as Exhibit 10.3 to our Registration Statement on Form S-4 filed on September 29, 2003, as thereafter amended). |
10.4 |
Security and Control Agreement, dated as of August 11, 2003, among KCI, U.S. Bank National Association, as Trustee, and U.S. Bank National Association, as Securities Intermediary (filed as Exhibit 10.4 to our Registration Statement on Form S-4 filed on September 29, 2003, as thereafter amended). |
10.5 |
Series A Preferred Stock Purchase Agreement, dated as of August 11, 2003, among KCI, the Non-Sponsor Investors, the Sponsor Investors, and the Director Investors (filed as Exhibit 10.5 to our Registration Statement on Form S-4 filed on September 29, 2003, as thereafter amended). |
10.6 |
Investors' Rights Agreement, dated as of August 11, 2003, among KCI, the Non-Sponsor Investors, the Sponsor Investors and the Director Investors (filed as Exhibit 10.6 to our Registration Statement on Form S-4 filed on September 29, 2003, as thereafter amended). |
10.7 |
Statement of Designations, Preferences and Rights of the Series A Convertible Participating Preferred Stock of Kinetic Concepts, Inc. (filed as Exhibit 10.7 to our Registration Statement on Form S-4 filed on September 29, 2003, as thereafter amended). |
10.8 |
Agreement Among Shareholders, dated as of November 5, 1997 (filed as Exhibit 10.8 to our Registration Statement on Form S-4 filed on September 29, 2003, as thereafter amended). |
10.9 |
Joinder and Amendment Agreement, dated as of June 25, 2003 (filed as Exhibit 10.9 to our Registration Statement on Form S-4 filed on September 29, 2003, as thereafter amended). |
10.10 |
Waiver and Consent, effective as of September 27, 2002 (filed as Exhibit 10.10 to our Registration Statement on Form S-4 filed on September 29, 2003, as thereafter amended). |
10.11 |
Amendment and Waiver, dated as of August 11, 2003 (filed as Exhibit 10.11 to our Registration Statement on Form S-4 filed on September 29, 2003, as thereafter amended). |
*31.1 |
Certification of Chief Executive Officer |
*31.2 |
Certification of Chief Financial Officer |
*Exhibit filed herewith. |
Table of Contents
(b) Reports on Form 8-K
1. Current Report on Form 8-K dated July 14, 2003. Regulation FD disclosure furnishing a press
release detailing financial results for the three months and six months ended June 30,2003.
2. Current Report on Form 8-K dated July 15, 2003 announcing the Company's intent to offer senior
subordinated notes.
3. Current Report on Form 8-K dated July 24, 2003 announcing the pricing of the Company's senior
subordinated notes.
4. Current Report on form 8-K dated August 1, 2003 announcing the commencement of a consent
solicitation relating to the Company's 9 5/8% senior subordinated notes due 2007.
5. Current Report on Form 8-K dated August 12, 2003 announcing that the Company
has completed key aspects of a recapitalization transaction.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
KINETIC CONCEPTS, INC
(REGISTRANT)
By: /s/ DENNERT O. WARE
Date: November 13, 2003 ____________________________
Dennert O. Ware
President and Chief Executive Officer
By: /s/ MARTIN J. LANDON
Date: November 13, 2003 ____________________________
Martin J. Landon
Vice President and Chief Financial Officer (Acting)
Table of Contents
CERTIFICATIONS
CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER
I, Dennert O. Ware, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Kinetic Concepts, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
c) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors:
a) All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls over financial reporting.
Date: November 13, 2003
/s/ Dennert O. Ware
Dennert O. Ware
President and Chief Executive Officer
Exhibit 31.2
CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER
I, Martin J. Landon, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Kinetic Concepts, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
c) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors:
a) All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls over financial reporting.
Date: November 13, 2003
/s/ Martin J. Landon
Martin J. Landon
Vice President and Chief Financial Officer (Acting)